<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">J Enzyme Inhib Med Chem</span><span class="iso-abbrev" title="iso-abbrev">J Enzyme Inhib Med Chem</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Journal of Enzyme Inhibition and Medicinal Chemistry</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">1475-6366</span><span class="issn-epub" tagx="issn" title="issn-epub">1475-6374</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Taylor &amp;amp; Francis</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7993375">7993375</a></span><span class="pmid" title="pmid"> pmid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/33730937">33730937</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1080/14756366.2021.1899168">10.1080/14756366.2021.1899168</a></span><span class="publisher-id" title="publisher-id">1899168</span><div class="unknown" title="article-version" tag="article-version">
Version of Record</div> <div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Research Article</span>: <span class="subject" title="subject">Research Paper</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect</div> <div class="alt-title" title="alt-title">
T. S. Ibrahim et al.</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0002-3049-4617</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ibrahim</span><span class="given-names" tagx="given-names" title="given-names">Tarek S.</span></span><a href="#AF0001">a</a><a href="#AF0002">b</a><a href="#AN0001" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hawwas</span><span class="given-names" tagx="given-names" title="given-names">Mohamed M.</span></span><a href="#AF0003">c</a></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0003-4178-0341</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Malebari</span><span class="given-names" tagx="given-names" title="given-names">Azizah M.</span></span><a href="#AF0001">a</a></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0002-1091-2885</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Taher</span><span class="given-names" tagx="given-names" title="given-names">Ehab S.</span></span><a href="#AF0003">c</a></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0002-9825-3465</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Omar</span><span class="given-names" tagx="given-names" title="given-names">Abdelsattar M.</span></span><a href="#AF0001">a</a><a href="#AF0004">d</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Neamatallah</span><span class="given-names" tagx="given-names" title="given-names">Thikryat</span></span><a href="#AF0005">e</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdel-Samii</span><span class="given-names" tagx="given-names" title="given-names">Zakaria K.</span></span><a href="#AF0002">b</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Safo</span><span class="given-names" tagx="given-names" title="given-names">Martin K.</span></span><a href="#AF0006">f</a><a href="#AN0002" /></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0003-4332-6345</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elshaier</span><span class="given-names" tagx="given-names" title="given-names">Yaseen A. M. M.</span></span><a href="#AF0007">g</a></span><span class="citation_author_institution" id="AF0001">[a], <span class="institution" title="institution">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University</span><span class="city" tagx="city" title="city">Jeddah</span><span class="country" tagx="country" title="country">Saudi Arabia</span></span><span class="citation_author_institution" id="AF0002">[b], <span class="institution" title="institution">Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University</span><span class="city" tagx="city" title="city">Zagazig</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0003">[c], <span class="institution" title="institution">Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University</span><span class="city" tagx="city" title="city">Assiut</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0004">[d], <span class="institution" title="institution">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University</span><span class="city" tagx="city" title="city">Cairo</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0005">[e], <span class="institution" title="institution">Department of Pharmacology and toxicology, Faculty of Pharmacy, King Abdulaziz University</span><span class="city" tagx="city" title="city">Jeddah</span><span class="country" tagx="country" title="country">Saudi Arabia</span></span><span class="citation_author_institution" id="AF0006">[f], <span class="institution" title="institution">Institute for Structural Biology, Drug Discovery and Development, Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University</span><span class="city" tagx="city" title="city">Richmond</span><span class="state" tagx="state" title="state">VA</span><span class="country" tagx="country" title="country">USA</span></span><span class="citation_author_institution" id="AF0007">[g], <span class="institution" title="institution">Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City</span><span class="city" tagx="city" title="city">Menoufia</span><span class="country" tagx="country" title="country">Egypt</span></span></div> <div class="author-notes" title="author-notes"> <div class="corresp" title="corresp">
CONTACT Tarek S. Ibrahim <span class="email" tagx="email" title="email">tmabrahem@kau.edu.sa, tarekeldeeb1976@yahoo.com</span><span class="institution" title="institution">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University</span>, <span class="city" tagx="city" title="city">Jeddah</span>, <span class="postal-code" tagx="postal-code" title="postal-code">21589</span>, <span class="country" tagx="country" title="country">Saudi Arabia</span></div> <div class="corresp" title="corresp">
Martin K. Safo <span class="email" tagx="email" title="email">msafo@vcu.edu</span><span class="institution" title="institution">Institute for Structural Biology, Drug Discovery and Development, Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University</span>, <span class="city" tagx="city" title="city">Richmond</span>, <span class="state" tagx="state" title="state">VA</span><span class="postal-code" tagx="postal-code" title="postal-code">23219</span>, <span class="country" tagx="country" title="country">USA</span></div> </div><span class="pub-date-" title="pub-date-">: <span>2021-3-3</span></span><span class="pub-date-" title="pub-date-">: <span>2021</span></span><span class="volume" tagx="volume" title="volume">36</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">802</span><span class="lpage" tagx="lpage" title="lpage">818</span><div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">The Author(s)</span>, <span class="copyright-year" tagx="copyright-year" title="copyright-year">2021</span></span><span class="license" title="license"> <div tag="license_ref">
https://creativecommons.org/licenses/by/4.0/</div><span class="license-p" title="license-p">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</span></span></div><a class="self-uri" href="IENZ_36_1899168.pdf" title="self-uri">IENZ_36_1899168.pdf</a><div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="title" tagx="title" title="title">
Abstract</div> <p>A new series of quinoline derivatives of combretastatin A-4 have been designed, synthesised and demonstrated as tubulin polymerisation inhibitors. These novel compounds showed significant antiproliferative activities, among them, <b>12c</b> exhibited the most potent inhibitory activity against different cancer cell lines (MCF-7, HL-60, HCT-116 and HeLa) with IC<sub>50</sub> ranging from 0.010 to 0.042â€‰ÂµM, and with selectivity profile against MCF-10A non-cancer cells. Further mechanistic studies suggest that <b>12c</b> can inhibit tubulin polymerisation and cell migration, leading to G<sub>2</sub>/M phase arrest. Besides, <b>12c</b> induces apoptosis <i>via</i> a mitochondrial-dependant apoptosis pathway and caused reactive oxygen stress generation in MCF-7 cells. These results provide guidance for further rational development of potent tubulin polymerisation inhibitors for the treatment of cancer. </p><ul> <div class="title" tagx="title" title="title">
Highlights</div> <li> <p>A novel series of quinoline derivatives of combretastatin A-4 have been designed and synthesised.</p> </li> <li> <p>Compound <b>12c</b> showed significant antiproliferative activities against different cancer cell lines.</p> </li> <li> <p>Compound <b>12c</b> effectively inhibited tubulin polymerisation and competed with [<sup>3</sup>H] colchicine in binding to tubulin.</p> </li> <li> <p>Compound <b>12c</b> arrested the cell cycle at G<sub>2</sub>/M phase, effectively inducing apoptosis and inhibition of cell migration.</p> </li> </ul> <p /> </div> <div class="abstract" title="abstract"> <div class="title" tagx="title" title="title">
Graphical Abstract</div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/" /></div>  </div> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
Combretastatin A-4</div> <div class="kwd" title="kwd">
quinoline</div> <div class="kwd" title="kwd">
apoptosis</div> </div> <div class="unknown" title="support-group" tag="support-group"> <div class="funding-group" title="funding-group"> <div class="funding" title="funding">
Funding</div> <div class="award-group" title="award-group"> <div class="funding-source" title="funding-source"> <div class="institution-wrap" title="institution-wrap"><span class="institution" title="institution">Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah</span><span class="institution-id" title="institution-id">10.13039/501100004686</span></div> </div><span class="award-id" tagx="award-id" title="award-id">RG-18â€"166-41</span></div> <div class="funding-statement" title="funding-statement">
This project was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant number [RG-18â€"166-41]. The authors, therefore, gratefully acknowledge DSR technical and financial support.</div> </div> </div> <div class="counts" title="counts"><span class="fig-count" title="fig-count">fig-count: </span><span class="table-count" title="table-count">table-count: </span><span class="page-count" title="page-count">page-count: </span><span class="word-count" title="word-count">word-count: </span></div> </div> </div> <div class="body" title="body"> <div class="introduction" title="sec"><span class="label" tagx="label" title="label">1.</span><div class="title" tagx="title" title="title">
Introduction</div> <p>Cancer is a disease of an uncontrolled growth and abnormal division of cells, which leads to death. In recent years, targeted antineoplastic agents have become an effective treatment choice for cancer<a href="#CIT0001"><sup>1</sup></a>, with pharmaceutical companies focussing on targeted therapies against different and special cancer types<a href="#CIT0002"><sup>2</sup></a>. Tubulin polymerisation inhibitors represent one of the most well-known and potential examples of such targeted cancer therapies<a href="#CIT0003"><sup>3</sup></a>. Tubulin is a globular protein that performs a substantial function in cell mitosis. Microtubules (MTs), which represent the basic constituents of eukaryotic cell, are cytoskeletons constructed by the association of Î±- and Î²-tubulin heterodimers with a head and tail pattern to form hollow cylindrical tubes (nearly 25â€‰nm in diameter)<a href="#CIT0004"><sup>4â€"7</sup></a>. MTs play a crucial role in many fundamental cellular activities, such as motility, cell formation, cell secretion, signalling, maintenance of cell shape, regulation of intracellular transport and cell division<a href="#CIT0008"><sup>8â€"10</sup></a>. Due to these multiple functions, microtubule system has become an attractive target for cancer chemotherapy<a href="#CIT0011"><sup>11</sup></a><sup>,</sup><a href="#CIT0012"><sup>12</sup></a>. Disruption of MTs or tubulin dynamics exposes the cell to mitotic arrest of the cell cycle at G<sub>2</sub>/M phase, and consequently induction of cellular apoptosis<a href="#CIT0013"><sup>13</sup></a><sup>,</sup><a href="#CIT0014"><sup>14</sup></a>. Several microtubule-interfering agents (MIAs) have been identified, e.g. paclitaxel, vincristine, and colchicine that are obtained from the natural products, taxol, vinca and colchicine, respectively. MIAs are known to bind to tubulin at specific binding sites that are classified as taxol, vinca and colchicine sites to either enhance or inhibit tubulin polymerisation.<a href="#CIT0015"><sup>15</sup></a> For example, microtubule stabilisers, e.g. paclitaxel stimulate microtubule polymerisation<a href="#CIT0016"><sup>16</sup></a>, while microtubule destabilizers, e.g. colchicine, and the vinca alkaloids vinblastine and vincristine inhibit polymerisation of microtubules<a href="#CIT0017"><sup>17</sup></a>.</p> <p>Significant attention is now focussed on colchicine binding site inhibitors due to their positive impact on ABC-transporter-mediated drug resistance<a href="#CIT0018"><sup>18</sup></a><sup>,</sup><a href="#CIT0019"><sup>19</sup></a>. Combretastatin A-4 (CA-4), (<b>1</b>, <a href="#F0001">Figure 1</a>) has been reported as the most potent antimitotic agent of this family against several tumour cells<a href="#CIT0020"><sup>20</sup></a>. CA-4 was first isolated from the bark of the willow tree <i>Combretum caffrum</i> from South Africa in 1989<a href="#CIT0021"><sup>21</sup></a>. CA-4 has a vascular disrupting activity against tumour cell vasculature by preventing blood supply to solid tumour, resulting in apoptosis<a href="#CIT0022"><sup>22â€"24</sup></a>. Given its structural simplicity, CA-4 has been studied as a lead pharmacophore for deciphering tubulin functions and properties<a href="#CIT0025"><sup>25</sup></a>. Phases II and III clinical studies are currently ongoing with tubulin-targeted drugs<a href="#CIT0024"><sup>24</sup></a><sup>,</sup><a href="#CIT0026"><sup>26</sup></a>. Structure activity relationships (SAR) studies with CA-4 have revealed three important structural features (<a href="#F0001">Figure 1</a>). These include: (i) a 3,4,5-trimethoxy moiety on ring A that is essential for activity; (ii) a <i>cis</i>-configuration of both aromatic rings that is essential for activity (<i>trans</i>-orientation is inactive); (iii) the presence of small substituent on ring B, e.g. methoxy group that is important for activity. The <i>cis</i>-alkene configuration in CA-4 allows the aromatic rings to assume optimal binding orientation for interactions with the colchicine binding site. Unfortunately, the <i>cis</i> configuration of CA-4 has a propensity for undergoing transformation to the inactive <i>trans</i> configuration upon storage and during <i>inÂ vivo</i> metabolism. To overcome this, many structural modifications of CA-4 have been undertaken where the <i>cis</i> double bond is replaced with heterocycles, either monocyclic, such as oxadiazole, isoxazole and imidazole, resulting in compounds, such as <b>1</b>, <b>2</b> and <b>3</b> respectively (<a href="#F0001">Figure 1</a>)<a href="#CIT0027"><sup>27â€"33</sup></a> or fused heterocyclic, such as pyrazolopyridines<a href="#CIT0034"><sup>34</sup></a>, triazolopyridines<a href="#CIT0035"><sup>35</sup></a> and triazolothiadiazine derivatives<a href="#CIT0036"><sup>36</sup></a>. These compounds, like CA-4 showed pronounced activity against a panel of cancer cell lines.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 1.</span></a></div>   <p>(A) Chemical structure of CA-4 and its analogues; (B) tubulin targeting agents bearing quinoline moiety.</p>   </div> <p>Quinoline derivatives are popular for the treatment of malaria<a href="#CIT0037"><sup>37</sup></a><sup>,</sup><a href="#CIT0038"><sup>38</sup></a>. Moreover, quinoline heterocyclic containing compounds demonstrate potent anticancer activities with different modes of actions, including inhibition of proteasome, tyrosine kinases, and tubulin polymerisation<a href="#CIT0039"><sup>39â€"41</sup></a>. Previous studies have reported the antiproliferative activity of CA-4, isoCA-4 or chalcone compounds containing quinoline scaffold, either as ring A bioisoster, e.g. <b>4a</b><a href="#CIT0023"><sup>23</sup></a> and <b>4b</b><a href="#CIT0042"><sup>42</sup></a> or ring B bioisoster, e.g. <b>4c</b><a href="#CIT0043"><sup>43â€"45</sup></a> and <b>4d</b><a href="#CIT0046"><sup>46</sup></a>. These compounds demonstrate the potential of the quinoline ring as a template for developing more promising tubulin polymerisation inhibitors and antiproliferative agents.</p> <p>In this work, we optimised CA-4 into a series of novel hybrid quinoline derivatives as potent tubulin inhibitor, which involves introducing a rigid oxazolone or imidazolone between rings A and B to maintain the cis configuration, as well as targeting the quinolyl moiety (ring B), by varying the electronic substituents effect while maintaining the 3,4,5-trimethoxyphenyl moiety as present in ring A of CA-4 (<a href="#F0002">Figure 2</a>). Following, we synthesised several analogues that constitute two classes of compounds: the oxazolones (Compounds <b>12aâ€"h)</b> and the imidazolones <b>(</b>Compounds <b>13aâ€"h</b>). The compounds have been screened for their antiproliferative activities against a variety of cancer cell lines, as well as studied for their mechanism of action. We expect the results to lead to better understanding of the mechanistic mode of the compoundsâ€™ activity against tubulin and provide guidance for further development of potent anticancer drugs.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 2.</span></a></div>   <p>Structure of CA-4 and our rationalised compounds.</p>   </div> </div> <div class="experimentalsection" title="sec"><span class="label" tagx="label" title="label">2.</span><div class="title" tagx="title" title="title">
Experimental section</div> <div class="chemistry" title="sec"><span class="label" tagx="label" title="label">2.1.</span><div class="title" tagx="title" title="title">
Chemistry</div> <p>Melting points were determined with a Gallenkamp (London, UK) melting point apparatus and are uncorrected. IR spectra (KBr, cm<sup>âˆ’1</sup>) were recorded on Bruker Vector, 22FT-IR [Fourier Transform Infra-red (FTIR), Germany] spectrometer. Unless otherwise specified, proton (<sup>1</sup>H) and carbon (<sup>13</sup>C) NMR spectra were recorded at room temperature in base filtered CDCl<sub>3</sub> on a spectrometer operating at 400 &amp;amp; 300â€‰MHz for proton and 100 &amp;amp; 75â€‰MHz for carbon nuclei. The signal due to residual CHCl<sub>3</sub> appearing at Î´ H 7.26 and (CH<sub>3</sub>)<sub>2</sub>SO appearing at Î´ H 2.5 and the central resonance of the CDCl<sub>3</sub> â€œtripletâ€� appearing at Î´ C 77.0 and for (CD<sub>3</sub>)<sub>2</sub>SO â€œmultipletâ€� appearing at Î´ C 39.0 were used to reference 1H and <sup>13</sup>C NMR spectra, respectively. <sup>1</sup>H NMR data are recorded as follows: chemical shift (Î´) [multiplicity, coupling constant(s) J (Hz), relative integral] where multiplicity is defined as sâ€‰=â€‰singlet; dâ€‰=â€‰doublet; tâ€‰=â€‰triplet; qâ€‰=â€‰quartette; and mâ€‰=â€‰multiplet or combinations of the above. Elemental analyses were determined using Manual Elemental Analyser Heraeus (Germany) and Automatic Elemental Analyser CHN Model 2400 Perkin Elmer (Waltham, MA, USA) at Microanalytical Centre, Faculty of Science, Cairo University, Egypt. All the elemental analyses results corresponded to calculated values within experimental error. Progress of reactions was monitored by thin-layer chromatography (TLC) using precoated TLC sheets with Ultraviolet (UV) fluorescent silica gel (Merck 60F254), and spots were visualised by iodine vapours or irradiation with UV light (254â€‰nm). All chemicals were purchased from Sigma-Aldrich or Lancaster Synthesis Corporation (UK). Intermediates <b>6â€"8aâ€"i</b> were prepared according to reported procedure<a href="#CIT0047"><sup>47</sup></a><sup>,</sup><a href="#CIT0048"><sup>48</sup></a>.</p> <div class="generalprocedureforpreparationofoxazolones(12aâ€" title="sec"><span class="label" tagx="label" title="label">2.1.1.</span><div class="title" tagx="title" title="title">
General procedure for preparation of oxazolones (12aâ€"h)</div> <p>A mixture of <i>N</i>-(3,4,5-trimethoxybenzoyl)glycine (0.30â€‰g, 1.10â€‰mmol) and the appropriate aldehydes <b>8aâ€"h</b> (1.00â€‰mmol) in acetic anhydride (1â€‰ml) and fused sodium acetate (0.1â€‰g, 1.2â€‰mmol) was heated on an oil bath at 80â€‰Â°C for 2â€‰h. After cooling down at room temperature the mixture was allowed to stand for 24â€‰h at 0â€‰Â°C. The precipitate was filtered off and washed three times with ice-cooled ethanol (10â€‰ml), and the product crystallised from ethanol.</p> <div class="4-[(2-methoxyquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.1.1.</span><div class="title" tagx="title" title="title">
4-[(2-Methoxyquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxyphenyl)oxazol-5(4H)-one (12a)</div> <p>Yellow solid, Yield (81%); m.p. 215â€"217â€‰Â°C. IR (KBr): Ï…â€‰=â€‰1776 (C=O), 1621 (C=N), 1599 (C=C) cm<sup>âˆ’1</sup>. <sup>1</sup>H NMR (400â€‰MHz, CDCl<sub>3</sub>) Î´: 9.48 (s, 1H, Ar-H), 7.86â€"7.81 (m, 2H, Ar-H), 7.71â€"7.67 (m, 2H, Ar-H), 7.45â€"7.41 (m, 3H, Ar-H), 4.15 (s, 3H, OCH<sub>3</sub>), 4.00 (s, 9H, 3 OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, CDCl<sub>3</sub>) Î´: 167.1, 163.9, 160.0, 153.5, 147.1, 143.1, 142.4, 134.6, 131.5, 128.9, 127.1, 125.2, 124.7, 123.6, 120.1, 118.5, 105.8, 61.1, 56.4, 54.1â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 420 (7.79) [M<sup>+</sup>]; Anal. Calcd for C<sub>23</sub>H<sub>20</sub>N<sub>2</sub>O<sub>6</sub>: C, 65.71; H, 4.80; N, 6.66. Found: C, 65.64; H, 4.74; N, 6.71</p> </div> <div class="4-[(2-methoxy-6-methylquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.1.2.</span><div class="title" tagx="title" title="title">
4-[(2-Methoxy-6-methylquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxyphenyl) oxazol-5(4H)-one (12b)</div> <p>Pale yellow solid, Yield (79%); m.p. 218â€"220â€‰Â°C. <sup>1</sup>H NMR (400â€‰MHz, CDCl<sub>3</sub>) Î´: 9.36 (s, 1H, Ar-H), 7.72 (t, <i>J</i>â€‰=â€‰4â€‰Hz, 2H, Ar-H), 7.56 (s, 1H, Ar-H), 7.49 (d, <i>J</i>â€‰=â€‰8.5â€‰Hz, 1H, Ar-H), 7.41 (s, 2H, Ar-H), 4.11 (s, 3H, OCH<sub>3</sub>), 3.98 (d, <i>J</i>â€‰=â€‰8.0â€‰Hz, 9H, 3OCH<sub>3</sub>) and 2.51 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, CDCl<sub>3</sub>) Î´: 167.2, 163.8, 159.7, 153.5, 145.7, 143.1, 141.8, 134.4, 134.3, 133.6, 127.8, 126.9, 125.1, 124.1, 120.3, 118.1, 110.0, 105.7, 61.1, 56.4, 53.9, 21.3â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 434 (9.79) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>22</sub>N<sub>2</sub>O<sub>6</sub>: C, 66.35; H, 5.10; N, 6.45. Found: C, 66.29; H, 5.04; N, 6.50.</p> </div> <div class="4-[(2-methoxy-7-methylquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.1.3.</span><div class="title" tagx="title" title="title">
4-[(2-Methoxy-7-methylquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxyphenyl) oxazol-5(4H)-one (12c)</div> <p>Yellow solid, Yield (84%); m.p. 233â€"235â€‰Â°C. <sup>1</sup>H NMR (400â€‰MHz, CDCl<sub>3</sub>) Î´: 9.50 (s, 1H, Ar-H), 7.76â€"7.73 (m, 3H, Ar-H),7.45 (s, 2H, Ar-H), 7.30â€"7.28 (m, 1H, Ar-H), 4.20 (s, 3H, OCH<sub>3</sub>), 4.00 (d, <i>J</i>â€‰=â€‰8.0â€‰Hz, 9H, 3 OCH<sub>3</sub>), 2.58 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, CDCl<sub>3</sub>) Î´: 167.2, 163.8, 162.6, 160.2, 153.5, 143.1, 142.8, 142.5, 134.3, 128.7, 127.0, 126.3, 123.9, 123.1, 120.2, 117.6, 105.7, 61.1, 56.4, 54.6, 22.1â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 434 (6.90) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>22</sub>N<sub>2</sub>O<sub>6</sub>: C, 66.35; H, 5.10; N, 6.45. Found: C, 66.32; H, 5.05; N, 6.47.</p> </div> <div class="4-[(2-methoxy-8-methylquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.1.4.</span><div class="title" tagx="title" title="title">
4-[(2-Methoxy-8-methylquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxyphenyl) oxazol-5(4H)-one (12d)</div> <p>Yellow solid, Yield (82%); m.p. 236â€"238â€‰Â°C. <sup>1</sup>H NMR (400â€‰MHz, CDCl<sub>3</sub>) Î´: 9.44 (s, 1H, Ar-H), 7.73 (s, 1H, Ar-H), 7.64 (d, <i>J</i>â€‰=â€‰8.0â€‰Hz, 1H, Ar-H), 7.52 (d, <i>J</i>â€‰=â€‰6.40â€‰Hz, 1H, Ar-H), 7.39 (s, 2H, Ar-H), 7.32â€"7.28 (m, 1H, Ar-H), 4.12 (s, 3H, OCH<sub>3</sub>), 3.98 (s, 9H, 3 OCH<sub>3</sub>), 2.68 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, CDCl<sub>3</sub>) Î´: 167.2, 163.8, 159.1, 153.7, 146.0, 143.1, 142.7, 135.4, 134.3, 131.6, 126.7, 125.0, 124.3, 124.0, 120.2, 118.0, 105.6, 61.1, 56.3, 53.7, 17.5â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 434 (9.50) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>22</sub>N<sub>2</sub>O<sub>6</sub>: C, 66.35; H, 5.10; N, 6.45. Found: C, 66.30; H, 5.04; N, 6.51.</p> </div> <div class="4-[2,6-dimethoxyquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.1.5.</span><div class="title" tagx="title" title="title">
4-[2,6-Dimethoxyquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxyphenyl)oxazol-5(4H)-one (12e)</div> <p>Yellow solid, Yield (84%); m.p. 242â€"244â€‰Â°C. 1784 (C=O), 1618 (C=N), 1586 (C=C) cm<sup>âˆ’1</sup>. <sup>1</sup>H NMR (400â€‰MHz, CDCl<sub>3</sub>) Î´: 9.33 (s, 1H, Ar-H), 7.73 (d, <i>J</i>â€‰=â€‰8.0â€‰Hz, 2H, Ar-H), 7.42â€"7.32 (m, 3H, Ar-H), 7.12 (s, 1H, Ar-H), 4.10 (s, 3H, OCH<sub>3</sub>), 3.99 (s, 9H, 3 OCH<sub>3</sub>) 3.93 (s, 3H, OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, CDCl<sub>3</sub>) Î´: 167.1, 163.8, 158.9, 156.4, 153.5, 143.2, 143.0, 141.1, 134.5, 128.5, 125.7, 124.2, 123.0, 120.2, 118.4, 107.4, 105.9, 61.2, 56.5, 55.6, 53.8â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 450 (8.40) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>22</sub>N<sub>2</sub>O<sub>7</sub>: C, 64.00; H, 4.92; N, 6.22. Found: C, 63.94; H, 4.87; N, 6.28.</p> </div> <div class="4-[(2,7-dimethoxyquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.1.6.</span><div class="title" tagx="title" title="title">
4-[(2,7-Dimethoxyquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxyphenyl)oxazol-5(4H)-one (12f)</div> <p>Yellow solid, Yield (84%); m.p. 221â€"223â€‰Â°C. <sup>1</sup>H NMR (400â€‰MHz, CDCl<sub>3</sub>) Î´: 9.39 (s, 1H, Ar-H), 7.70â€"7.66 (m, 2H, Ar-H), 7.38 (s, 2H, Ar-H), 7.16 (s, 1H, Ar-H), 7.04 (d, <i>J</i>â€‰=â€‰8.0â€‰Hz, 1H, Ar-H), 4.11 (s, 3H, OCH<sub>3</sub>), 3.97 (s, 9H, 3OCH<sub>3</sub>) 3.95 (s, 3H, OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, CDCl<sub>3</sub>) Î´: 167.4, 163.3, 162.8, 160.7, 153.5, 149.7, 142.8, 142.0, 133.3, 130.2, 124.4, 120.4, 120.1, 117.2, 115.9, 106.4, 105.5, 61.2, 56.2, 55.6, 53.9â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 450 (7.30) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>22</sub>N<sub>2</sub>O<sub>7</sub>: C, 64.00; H, 4.92; N, 6.22. Found: C, 63.96; H, 4.96; N, 6.25.</p> </div> <div class="4-[(7-isopropoxy-2-methoxyquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.1.7.</span><div class="title" tagx="title" title="title">
4-[(7-Isopropoxy-2-methoxyquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxy phenyl)oxazol-5(4H)-one (12g)</div> <p>Yellow solid, Yield (77%); m.p. 227â€"229â€‰Â°C. <sup>1</sup>H NMR (400â€‰MHz, CDCl<sub>3</sub>) Î´ ppm: 9.41 (s, 1H, Ar-H), 7.74â€"7.67 (m, 2H, Ar-H), 7.41 (s, 2H, Ar-H),7.16â€"7.00 (m, 2H, Ar-H), 4.87â€"4.76 (m, 1H, OCH-), 4.12 (s, 3H, OCH<sub>3</sub>), 3.98 (s, 9H, 3 OCH<sub>3</sub>), 1.45 (d, <i>J</i>â€‰=â€‰4.0â€‰Hz, 6H, 2 CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, CDCl<sub>3</sub>) Î´: 167.4, 163.1, 161.2, 160.7, 153.5, 149.5, 142.9, 141.9, 133.2, 130.3, 124.6, 120.4, 119.9, 118.2, 115.7, 107.9, 105.5, 70.3, 61.3, 56.4, 53.9, 22.0â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 478 (9.50) [M<sup>+</sup>]; Anal. Calcd for C<sub>26</sub>H<sub>26</sub>N<sub>2</sub>O<sub>7</sub>: C, 65.26; H, 5.48; N, 5.85. Found: C, 65.21; H, 5.45; N, 5.91.</p> </div> <div class="4-[(7-(benzyloxy)-2-methoxyquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.1.8.</span><div class="title" tagx="title" title="title">
4-[(7-(Benzyloxy)-2-methoxyquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxy phenyl)oxazol-5(4H)-one (12h)</div> <p>Pale yellow solid, Yield (73%); m.p. 247â€"249â€‰Â°C. <sup>1</sup>H NMR (400â€‰MHz, CDCl<sub>3</sub>) Î´: 9.43 (s, 1H, Ar-H), 7.72 (t, <i>J</i>â€‰=â€‰8â€‰Hz, 2H, Ar-H), 7.51â€"7.35 (m, 6H, Ar-H), 7.28â€"7.26 (m, 2H, Ar-H), 7.14 (d, 1H, <i>J</i>â€‰=â€‰8.0â€‰Hz, 1H, Ar-H), 5.21 (s, 2H, OCH<sub>2</sub>âˆ’), 4.12 (s, 3H, OCH<sub>3</sub>), 3.98 (s, 9H, 3 OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, CDCl<sub>3</sub>) Î´: 167.4, 163.3, 161.9, 160.8, 153.5, 149.4, 142.9, 141.9, 136.2, 133.5, 130.2, 128.7, 128.3, 127.7, 124.4, 120.4, 120.3, 117.5, 116.0, 107.5, 105.6, 70.3, 61.3, 56.4, 53.9â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 526 (7.30) [M<sup>+</sup>]; Anal. Calcd for C<sub>30</sub>H<sub>26</sub>N<sub>2</sub>O<sub>7</sub>: C, 68.43; H, 4.98; N, 5.35. Found: C, 68.39; H, 4.92; N, 5.41.</p> </div> </div> <div class="generalprocedureforpreparationof(13aâ€" title="sec"><span class="label" tagx="label" title="label">2.1.2.</span><div class="title" tagx="title" title="title"><i>General procedure for preparation of</i> (13aâ€"h)</div> <p>The appropriate oxazolones <b>12aâ€"h</b> (1â€‰mmol) was stirred and heated under reflux in ethanol (10â€‰ml) containing ammonium hydroxide (10â€‰ml), and the reaction monitored by TLC. After completion of the reaction in 24â€‰h, the solvent was concentrated and cooled, and the precipitate was filtered off and crystallised from ethanol.</p> <div class="5-[(2-methoxyquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.2.1.</span><div class="title" tagx="title" title="title">
5-[(2-Methoxyquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxyphenyl)-3,5-dihydro-4H-imidazol-4-one (13a)</div> <p>Yellow solid, Yield (81%); m.p. 230â€"232â€‰Â°C. IR (KBr): Ï…â€‰=â€‰3222 (NH), 1709 (C=O), 1642 (C=N), 1615, 1589 (C=C) cm<sup>âˆ’1</sup>. <sup>1</sup>H NMR (400â€‰MHz, DMSO-d<sub>6</sub>) Î´: 12.22 (s, 1H, exch., NH), 9.69 (s, 1H, Ar-H), 8.03 (d, <i>J</i>â€‰=â€‰8.0â€‰Hz, 1H, Ar-H), 7.80â€"7.70 (m, 2H, Ar-H), 7.59 (s, 2H, Ar-H), 7.49 (t, <i>J</i>â€‰=â€‰8.0â€‰Hz, 1H, Ar-H), 7.28 (s, 1H, Ar-H), 4.11 (s, 3H, OCH<sub>3</sub>), 3.94 (s, 6H, 2OCH<sub>3</sub>), 3.80 (s, 3H, OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, DMSO-d<sub>6</sub>) Î´: 187.4, 165.0, 164.2, 161.3, 157.9, 153.5, 146.7, 140.9, 132.2, 128.9, 126.7, 125.2, 123.9, 118.4, 108.7, 104.2, 60.3, 56.3, 54.1â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 419 (5.40) [M<sup>+</sup>]; Anal. Calcd for C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub>: C, 65.86; H, 5.05; N, 10.02. Found: C, 65.81; H, 4.99; N, 10.09.</p> </div> <div class="5-[(2-methoxy-6-methylquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.2.2.</span><div class="title" tagx="title" title="title">
5-[(2-Methoxy-6-methylquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxyphenyl)-3,5-dihydro-4H-imidazol-4-one (13b)</div> <p>Yellow solid, Yield (81%); m.p. 223â€"225â€‰Â°C. <sup>1</sup>HNMR (400â€‰MHz, DMSO-d<sub>6</sub>) Î´: 12.18 (s, 1H, exch., NH), 9.55 (s, 1H, Ar-H), 7.74â€"7.54 (m, 5H, Ar-H), 7.26â€"7.24 (d, <i>J</i>â€‰=â€‰6.6â€‰Hz, 1H, Ar-H), 4.07 (s, 3H, OCH<sub>3</sub>), 3.93 (s, 6H, OCH<sub>3</sub>), 3.80 (s, 3H, OCH<sub>3</sub>), 2.47 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, DMSO-d<sub>6</sub>) Î´: 172.0, 162.2, 156.0, 153.7, 144.6, 142.6, 142.4, 141.2, 134.4, 133.4, 128.1, 126.8, 125.4, 123.2, 119.3, 116.2, 110.0, 106.2, 60.7, 56.8, 54.2, 21.3â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 433 (5.60) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub>: C, 66.50; H, 5.35; N, 9.69. Found: C, 66.41; H, 5.28; N, 9.75.</p> </div> <div class="5-[(2-methoxy-7-methylquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.2.3.</span><div class="title" tagx="title" title="title">
5-[(2-Methoxy-7-methylquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxyphenyl)-3,5-dihydro-4H-imidazol-4-one (13c)</div> <p>Yellow solid, Yield (84%); m.p. 236â€"238â€‰Â°C. IR (KBr): Ï…â€‰=â€‰3215 (NH), 1711 (C=O), 1639 (C=N), 1590 (C=C) cm<sup>âˆ’1</sup>. <sup>1</sup>H NMR (400â€‰MHz, DMSO-d<sub>6</sub>) Î´: 12.17 (s, 1H, exch. NH), 9.63 (s, 1H, Ar-H), 7.92 (d, <i>J</i>â€‰=â€‰8.0â€‰Hz, 1H, Ar-H), 7.58 (s, 3H, Ar-H), 7.32 (d, <i>J</i>â€‰=â€‰8â€‰Hz, 1H, Ar-H), 7.27 (s, 1H, Ar-H), 4.09 (s, 3H, OCH<sub>3</sub>), 3.94 (s, 6H, 2OCH<sub>3</sub>), 3.80 (s, 3H, OCH<sub>3</sub>), 2.53 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, DMSO-d<sub>6</sub>) Î´: 162.6, 162.5, 160.3, 153.9, 142.2, 141.5, 129.1, 127.1, 126.3, 123.6, 118.3, 115.8, 105.6, 60.8, 56.5, 54.2, 22.0â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 433 (8.40) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub>: C, 66.50; H, 5.35; N, 9.69. Found: C, 66.44; H, 5.32; N, 9.72.</p> </div> <div class="5-[(2-methoxy-8-methylquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.2.4.</span><div class="title" tagx="title" title="title">
5-[(2-Methoxy-8-methylquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxy phenyl)-3,5-dihydro-4H-imidazol-4-one (13d)</div> <p>Yellow solid, Yield (82%); m.p. 233â€"235â€‰Â°C. <sup>1</sup>H NMR (400â€‰MHz, DMSO-d<sub>6</sub>) Î´: 12.16 (s, 1H, exch., NH), 9.59 (s, 1H, Ar-H), 7.80 (s, 1H, Ar-H), 7.70 (d, <i>J</i>â€‰=â€‰8â€‰Hz, 1H, Ar-H), 7.59â€"7.56 (m, 3H, Ar-H), 7.29 (s, 1H, Ar-H), 4.10 (s, 3H, OCH<sub>3</sub>), 3.95 (s, 6H, 2OCH<sub>3</sub>), 3.80 (s, 3H, OCH<sub>3</sub>), 2.49 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, DMSO-d<sub>6</sub>) Î´: 161.9, 158.2, 153.3, 142.2, 141.6, 141.5, 134.2, 131.3, 126.7, 124.8, 124.5, 118.6, 115.4, 105.3, 60.2, 56.1, 53.5, 17.1â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 433 (7.12) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub>: C, 66.50; H, 5.35; N, 9.69. Found: C, 66.47; H, 5.30; N, 9.73.</p> </div> <div class="5-[(2,6-dimethoxyquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.2.5.</span><div class="title" tagx="title" title="title">
5-[(2,6-Dimethoxyquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxyphenyl)-3,5-dihydro-4H-imidazol-4-one (13e)</div> <p>Yellow solid, Yield (84%); m.p. 253â€"255â€‰Â°C. <sup>1</sup>HNMR (400â€‰MHz, DMSO-d<sub>6</sub>) Î´: 12.03 (s, 1H, exchangeable, NH), 9.50 (s, 1H, Ar-H), 7.83â€"7.77 (m, 1H, Ar-H), 7.53 (s, 2H, Ar-H), 7.48 (s, 1H, Ar-H), 7.20â€"7.05 (m, 2H, Ar-H), 4.04 (s, 3H, OCH<sub>3</sub>), 3.90 (s, 9H, 3 OCH<sub>3</sub>), 3.79 (s, 3H, OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, DMSO-d<sub>6</sub>) Î´: 164.6, 161.9, 157.1, 156.9, 154.1, 142.8, 141.9, 140.0, 128.4, 125.1, 124.1, 118.9, 110.0, 109.3, 108.0, 105.3, 60.7, 57.0, 56.2, 54.4â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 449 (8.35) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>6</sub>: C, 64.16; H, 5.16; N, 9.35. Found: C, 64.11; H, 5.12; N, 9.31.</p> </div> <div class="5-[(2,7-dimethoxyquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.2.6.</span><div class="title" tagx="title" title="title">
5-[(2,7-Dimethoxyquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxyphenyl)-3,5-dihydro-4H-imidazol-4-one (13f)</div> <p>Yellow solid, Yield (86%); m.p. 241â€"243â€‰Â°C. <sup>1</sup>HNMR (400â€‰MHz, DMSO-d<sub>6</sub>) Î´: 12.10 (s, 1H, exch., NH), 9.57 (s, 1H, Ar-H), 7.86 (d, <i>J</i>â€‰=â€‰8.0â€‰Hz, 1H, Ar-H), 7.53 (s, 2H, Ar-H), 7.23 (s, 1H, Ar-H), 7.15â€"7.08 (m, 2H, Ar-H), 4.07 (s, 3H, OCH<sub>3</sub>), 3.92 (s, 6H, 2OCH<sub>3</sub>), 3.79 (s, 3H, OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, DMSO-d<sub>6</sub>) Î´: 163.9, 162.6, 161. 5, 158.3, 153.3, 149.0, 140.7, 140.3, 129.9, 118.7, 118.2, 117.4, 106.3, 105.7, 104.1, 60.1, 56.3, 55.7, 54.1â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 449 (5.65) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>6</sub>: C, 64.16; H, 5.16; N, 9.35. Found: C, 64.13; H, 5.10; N, 9.29.</p> </div> <div class="5-((7-isopropoxy-2-methoxyquinolin-3-yl)methylene)-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.2.7.</span><div class="title" tagx="title" title="title">
5-((7-Isopropoxy-2-methoxyquinolin-3-yl)methylene)-2â€"(3,4,5-trimethoxy phenyl)-3,5-dihydro-4H-imidazol-4-one (13g)</div> <p>Yellow solid, Yield (77%); m.p. 238â€"240â€‰Â°C. <sup>1</sup>HNMR (400â€‰MHz, DMSO-d<sub>6</sub>) Î´: 12.19 (s, 1H, exch.,NH), 9.61 (s, 1H, Ar-H), 7.92 (d, <i>J</i>â€‰=â€‰8.0â€‰Hz, 1H, Ar-H), 7.58 (s, 2H, Ar-H), 7.28 (s, 1H, Ar-H), 7.17 (s, 1H, Ar-H), 7.09â€"7.07 (d, <i>J</i>â€‰=â€‰8.0â€‰Hz, 1H, Ar-H), 4.90â€"4.83 (m, 1H, OCH), 4.09 (s, 3H, OCH<sub>3</sub>), 3.94 (s, 6H, 2OCH<sub>3</sub>), 3.79 (s, 3H, OCH<sub>3</sub>), 1.37 (s, 3H, CH<sub>3</sub>) 1.36 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100â€‰MHz, DMSO<i>-</i>d<sub>6</sub>) Î´: 164.2, 161.3, 156.7, 154.2, 153.5, 142.0, 140.9, 139.7, 128.1, 124.8, 122.4, 118.6, 109.2, 108.5, 104.3, 69.8, 60.3, 56.3, 53.9, 21.7â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 477 (9.25) [M<sup>+</sup>]; Anal. Calcd for C<sub>26</sub>H<sub>27</sub>N<sub>3</sub>O<sub>6</sub>: C, 65.40; H, 5.70; N, 8.80. Found: C, 65.35; H, 5.66; N, 8.86.</p> </div> <div class="5-[(7-(benzyloxy)-2-methoxyquinolin-3-yl)methylene]-2â€" title="sec"><span class="label" tagx="label" title="label">2.1.2.8.</span><div class="title" tagx="title" title="title">
5-[(7-(Benzyloxy)-2-methoxyquinolin-3-yl)methylene]-2â€"(3,4,5-trimethoxy phenyl)-3,5-dihydro-4H-imidazol-4-one (13h)</div> <p>Yellow solid, Yield (73%); m.p. 259â€"261â€‰Â°C. <sup>1</sup>H NMR (400â€‰MHz, DMSO-d<sub>6</sub>) Î´: 12.16 (s, 1H, exch., NH), 9.62 (s, 1H, Ar-H), 7.96â€"7.94 (d, <i>J</i>â€‰=â€‰8â€‰Hz, 1H, Ar-H), 7.58â€"7.28 (m, 10H, ArH), 5.30 (s, 2H, OCH<sub>2</sub>-), 4.09 (s, 3H, OCH<sub>3</sub>), 3.94 (s, 6H, 2OCH<sub>3</sub>), 3.79 (s, 3H, OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (400â€‰MHz, DMSO-d<sub>6</sub>) Î´: 163.9, 161.6, 158.5, 153.5, 148.8, 140.7, 140.3, 136.6, 130.2, 128.5, 128.0, 127.8, 118.9, 118.5, 117.8, 107.2, 105.9, 104.0, 69.7, 60.4, 56.3, 54.0â€‰ppm. MS (70â€‰eV): <i>m/z</i> (%): 525 (6.75) [M<sup>+</sup>]; Anal. Calcd for C<sub>30</sub>H<sub>27</sub>N<sub>3</sub>O<sub>6</sub>: C, 68.56; H, 5.18; N, 8.00. Found: C, 68.51; H, 5.13; N, 8.05.</p> </div> </div> </div> <div class="biochemicalevaluationofactivity" title="sec"><span class="label" tagx="label" title="label">2.2.</span><div class="title" tagx="title" title="title">
Biochemical evaluation of activity</div> <p>All biochemical assays were performed in triplicate on at least three independent occasions for the determination of mean values.</p> <div class="cellculture" title="sec"><span class="label" tagx="label" title="label">2.2.1.</span><div class="title" tagx="title" title="title">
Cell culture</div> <p>The four human tumour cell lines MCF-7, HCT-116, HL-60 and HeLa used in this study were obtained from the VACSERA (Giza, Egypt) cell culture unit that were originally acquired from ATCC (Manassas, VA, USA). All the human tumour cell lines were cultured in Dulbeccoâ€™s Modified Eagleâ€™s Medium (DMEM) with 10% foetal bovine serum, 2â€‰mM L-glutamine and 100â€‰Âµg/mL penicillin/streptomycin. Cells were maintained at 37ËšC in 5% CO<sub>2</sub> in a humidified incubator. All cells were sub-cultured 3 times/week by trypsinisation using TrypLE Express (1X).</p> </div> <div class="cellviabilityassay" title="sec"><span class="label" tagx="label" title="label">2.2.2.</span><div class="title" tagx="title" title="title">
Cell viability assay</div> <p>The quinoline compounds were evaluated for antiproliferative effect using the MTT viability assay of four cancer cell lines (MCF-7, HCT-116, HL-60 and HeLa) and normal breast cells MCF-10A to calculate the relative IC<sub>50</sub> values for each compound. Cells were seeded in triplicate in 96-well plates at a density of 10 Ã— 10<sup>3</sup> cells/ml in a total volume of 200â€‰Âµl per well. 0.1% of DMSO was used as a vehicle control. Following, the cells were treated with 2â€‰Âµl test compound (from stock solutions in ethanol) to furnish the concentration range of study, 1â€‰nM to 50â€‰ÂµM, and re-incubated for a further 72â€‰h. The culture medium was then removed, and the cells washed with 100â€‰ÂµL phosphate buffered saline (PBS) and 50â€‰ÂµL MTT added, to reach a final concentration of 1â€‰mg/mL. Cells were incubated for 2â€‰h in darkness at 37â€‰Â°C. Solubilisation was begun through the addition of 200â€‰ml DMSO, and the cells maintained at room temperature in darkness for 20â€‰min to ensure thorough colour diffusion before reading the absorbance. Plates were incubated for 72â€‰h at 37â€‰Â°Câ€‰+â€‰5% CO<sub>2</sub>. The MTT (5â€‰mg/mL in PBS) was added and incubated for another 4â€‰h, and the optical density was detected with a microplate reader at 570â€‰nm. Results were expressed as percentage viability relative to vehicle control (100%). Dose response curves were plotted and IC<sub>50</sub> values (concentration of drug resulting in 50% reduction in cell survival) were obtained using the commercial software package Prism (GraphPad Software, Inc., La Jolla, CA, USA). All the experiments were repeated in at least three independent experiments.</p> </div> <div class="tubulinpolymerisationassay" title="sec"><span class="label" tagx="label" title="label">2.2.3.</span><div class="title" tagx="title" title="title">
Tubulin polymerisation assay</div> <p>The assembly of purified bovine tubulin was monitored using a kit, BK006, purchased from Cytoskeleton Inc., (Denver, CO, USA). The assay was carried out in accordance with the manufacturerâ€™s instructions using the standard assay conditions<a href="#CIT0049"><sup>49</sup></a>. Briefly, purified (&amp;gt;99%) bovine brain tubulin (3â€‰mg/mL) in a buffer consisting of 80â€‰mM PIPES (pH 6.9), 0.5â€‰mM EGTA, 2â€‰mM MgCl<sub>2</sub>, 1â€‰mM GTP and 10% glycerol was incubated at 37â€‰Â°C in the presence of either vehicle (2% (v/v) ddH<sub>2</sub>O), CA-4, or the quinoline compounds. Light is scattered proportionally to the concentration of polymerised microtubules in the assay. Therefore, tubulin assembly was monitored turbidimetrically at 340â€‰nm in a Spectramax 340â€‰PC spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). The concentration that inhibits tubulin polymerisation by 50% (IC<sub>50</sub>) was determined using area under the curve (AUC). The AUC of the untreated controls were considered as 100% polymerisation. The IC<sub>50</sub> value for each compound was computed using GraphPad Prism Software.</p> </div> <div class="colchicinesitecompetitivebindingassay" title="sec"><span class="label" tagx="label" title="label">2.2.4.</span><div class="title" tagx="title" title="title">
Colchicine site competitive binding assay</div> <p>The affinity of compounds <b>12c</b> to colchicine binding site was determined using Colchicine Site Competitive Assay kit CytoDYNAMIX Screen15 (Cytoskeleton, Inc., Denver, CO, USA) using the standard protocol of the manufacturer to determine Ki. Biotin-labelled tubulin (0.5â€‰Âµg) in 10â€‰ÂµL of reaction buffer was mixed with [3H]colchicine (0.08â€‰ÂµM, PerkinElmer, Waltham, MA) and the test compounds (positive control colchicine, negative control vinblastine, G-1, fluorescent G-1, or 2-ME) in a 96-well plate (final volume: 100â€‰ÂµL). After incubating for 2â€‰h at 37â€‰Â°C with gentle shaking, streptavidin-labelled yttrium SPA beads (80â€‰Âµg in 20â€‰ÂµL reaction buffer, PerkinElmer, Waltham, MA) were added to each well and incubated for 30â€‰min at 4â€‰Â°C. The plates were then read on a scintillation counter (Packard Instrument, Topcount Microplate Reader) and the percentage of inhibition was calculated<a href="#CIT0050"><sup>50</sup></a><sup>,</sup><a href="#CIT0051"><sup>51</sup></a>.</p> </div> <div class="cellcycleanalysis" title="sec"><span class="label" tagx="label" title="label">2.2.5.</span><div class="title" tagx="title" title="title">
Cell cycle analysis</div> <p>MCF-7 cells were seeded at a density of 1â€‰Ã—â€‰10<sup>5</sup> cells/well in 6-well plates and treated with CA-4 (50â€‰nM) and compound <b>12c</b> (50 and 250â€‰nM) for 24, 48 and 72â€‰h. The cells were collected by trypsinisation and centrifuged at 800Ã—<i>g</i> for 15â€‰min. Cells were washed twice with ice-cold PBS and fixed in ice-cold 70% ethanol overnight at âˆ’20â€‰Â°C. Fixed cells were centrifuged at 800Ã—<i>g</i> for 15â€‰min and stained with 50â€‰Âµg/mL of PI, containing 50â€‰Âµg/mL of DNase-free RNase A, at 37â€‰Â°C for 30â€‰min. The DNA content of cells (10,000 cells/experimental group) was analysed by flow cytometer at 488â€‰nm using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) and all data were recorded and analysed using the CellQuest Software (Becton-Dickinson).</p> </div> <div class="annexinv/piapoptoticassay" title="sec"><span class="label" tagx="label" title="label">2.2.6.</span><div class="title" tagx="title" title="title">
Annexin V/PI apoptotic assay</div> <p>Apoptotic cell death was detected by flow cytometry using Annexin V and propidium iodide (PI). MCF-7 Cells were seeded in 6 well plated at density of 1 Ã— 10<sup>5</sup> cells/mL and treated with vehicle (0.1% (v/v) EtOH), positive control (CA-4) or compound <b>12c</b> (50 and 250â€‰nM) for 24, 48 and 72â€‰h. Cells were then harvested and prepared for flow cytometric analysis. Cells were washed in 1X binding buffer (20X binding buffer: 0.1â€‰M HEPES, pH 7.4; 1.4â€‰M NaCl; 25â€‰mM CaCl<sub>2</sub> diluted in dH<sub>2</sub>O) and incubated in the dark for 30â€‰min on ice in Annexin V-containing binding buffer [1:100]. Cells were then washed once in binding buffer and then re-suspended in PI-containing binding buffer [1:1000]. Samples were analysed immediately using the BD accuri flow cytometer and prism software for analysis the data. Four populations are produced during the assay Annexin V and PI negative (Q4, healthy cells), Annexin V positive and PI negative (Q3, early apoptosis), Annexin V and PI positive (Q2, late apoptosis) and Annexin V negative and PI positive (Q1, necrosis).</p> </div> <div class="evaluationofexpressionlevelsofanti-apoptoticproteinsbcl-2,pro-apoptoticproteinsbaxandcaspase9" title="sec"><span class="label" tagx="label" title="label">2.2.7.</span><div class="title" tagx="title" title="title">
Evaluation of expression levels of anti-apoptotic proteins bcl-2, pro-apoptotic proteins bax and caspase 9</div> <p>The level of the anti-apoptotic marker and apoptotic marker BAX were assessed using Bcl-2 Elisa kit and human Bax ELISA Kit purchased from Zymed laboratories, invitrogen and Cloud-Clone Crop. (Katy, TX, USA), respectively, following the manufacturerâ€™s instructions. Briefly, Treated MCF-7 cell lysate with 250â€‰nM of compound <b>12c</b> were prepared, and equal amount of cell lysates were loaded and propped with specific antibodies. The samples were measured and analysed at 450â€‰nm in ROBONEK P2000 ELISA reader<a href="#CIT0052"><sup>52</sup></a>. <i>InÂ Vitro</i> Caspase-9 Activation Assay was performed using human active caspase-9 Invitrogen EIA kit according to the manufacturerâ€™s instructions. Compound <b>12c</b> at concentrations of 50 and 250â€‰nM and CA-4 (50â€‰nM) were prepared in dH<sub>2</sub>O up to a final volume of 50â€‰ÂµL/well followed by addition of 5â€‰ÂµL of active caspase-9. Following, the cells were mixed and 50â€‰ÂµL of the Master Mix was added to each well and allowed to react at 37â€‰Â°C for 1â€‰h. The fluorescence intensity of the test samples was recorded and analysed in a fluorescence plate reader at 400â€‰nm excitation and 505â€‰nm emissions. All experiments were conducted in triplicates.</p> </div> <div class="colonyformationassay" title="sec"><span class="label" tagx="label" title="label">2.2.8.</span><div class="title" tagx="title" title="title">
Colony formation assay</div> <p>MCF-7 cells (600 cells per well) were seeded in 6-well plates and incubated for 24â€‰h before being then treated with different doses of the compound <b>12c</b> (50 and 250â€‰nM) for 14â€‰days. Following, the cells were washed with PBS twice and subsequently fixed with 4% paraformaldehyde and stained with 0.05% crystal violet for 30â€‰min. Finally, cells were visualised using an inverted microscope.</p> </div> <div class="woundhealingassay" title="sec"><span class="label" tagx="label" title="label">2.2.9.</span><div class="title" tagx="title" title="title">
Wound healing assay</div> <p>MCF-7 were grown in 6-well plates for 24â€‰h, and scratches were made using pipette tip and washed with PBS to remove non-adherent cell debris. Subsequently, the cells were treated with different concentrations of <b>12c</b> for 24â€‰h. The migrations across the wound area were photographed under a phase contrast microscopy.</p> </div> <div class="measurementofmitochondrialdepolarisationeffect(Î" title="sec"><span class="label" tagx="label" title="label">2.2.10.</span><div class="title" tagx="title" title="title">
Measurement of mitochondrial depolarisation effect (Î"Ïˆ<sub>mt</sub>) and ROS levels in cells</div> <p>Mitochondrial membrane potential (Î"Ïˆ<sub>mt</sub>) was measured by flow cytometry with DiOC2(3) staining and additional labelling with an annexin V conjugate. After treatment with compound <b>12c</b> (50 and 250â€‰nM) and CA-4 (50â€‰nM), cells were stained with DiOC2(3) dye for 30â€‰min in the incubator, then harvested and washed with PBS. DiOC2(3)-stained cells were resuspended with 1X annexin binding buffer, followed by addition of annexin V conjugate and incubated at 37â€‰Â°C for 15â€‰min. The data from the flow cytometry were analysed by Cell Quest software. Production of intracellular reactive oxygen species (ROS) was measured using 2,7â€"dichlorofluorescin diacetate (H<sub>2</sub>-DCFDA) dye. MCF-7 cells were seeded and treated either with vehicle (0.1% DMSO) or with compound <b>12c</b> (50 and 250â€‰nM) or CA-4 (50â€‰nM) for 6, 12 and 24â€‰h. H<sub>2</sub>O<sub>2</sub> was used as a positive control. The amount of ROS generated was estimated after 2â€‰h of selected compound treatment. The cells were collected by centrifugation and washed twice with PBS. Cells were then incubated with DCFDA dye (25â€‰ÂµM) in dark at 37â€‰Â°C for 1â€‰h. Fluorescence spectra (510â€‰âˆ’â€‰600â€‰nm) were monitored using an excitation wavelength of 488â€‰nm<a href="#CIT0053"><sup>53</sup></a><sup>,</sup><a href="#CIT0054"><sup>54</sup></a>.</p> </div> </div> </div> <div class="results" title="results"><span class="label" tagx="label" title="label">3.</span><div class="title" tagx="title" title="title">
Results and discussion</div> <div class="designandchemistry" title="sec"><span class="label" tagx="label" title="label">3.1.</span><div class="title" tagx="title" title="title">
Design and chemistry</div> <p>The natural product, Combretastatin A-4 (CA-4; <a href="#F0001">Figure 1</a>) exhibits significant antiproliferative activities against several tumour cells by binding to the colchicine site of tubulin to inhibit the protein polymerisation<a href="#CIT0020"><sup>20</sup></a>. However, the <i>cis</i> double bond of CA-4 has a propensity to isomerise into the inactive <i>trans</i> configuration, leading to reduction in the moleculeâ€™s pharmacologic activity. Several structural modifications of the CA-4 pharmacophore have subsequently been undertaken to overcome this disadvantage, e.g. replacing the <i>cis</i> double bond with a heterocycle, oxadiazole, isoxazole and imidazole, resulting in compounds, such as <b>1</b>, <b>2</b> and <b>3</b> respectively (<a href="#F0001">Figure 1</a>)<a href="#CIT0027"><sup>27â€"32</sup></a>. In this work, we undertook a rational design approach of introducing chalcone system (ring C) in the form of either oxazolone or imidazolone between the two rings A and B, as well as isosterically replace ring B with quinolone. Specifically, the rigidity of the molecules was increased by introducing 1,3-oxazol-5-ones and 1,3-imidazol-4-ones to the <i>cis-</i>olefinic bond of CA-4, which we anticipate would create a desirable conformational and configurational restriction to prevent isomerisation of CA-4 into the inactive <i>trans</i>-isomer, as well as improve on the anticancer activities of these compounds since chalcones are well known for their anticancer properties<a href="#CIT0055"><sup>55</sup></a><sup>,</sup><a href="#CIT0056"><sup>56</sup></a>. The second design step involves varying the electronic substituents effect on the quinolyl moiety (ring B), while maintaining the natural active compound 3,4,5-trimethoxyphenyl moiety, which we anticipate will increase the potency of these compounds.</p> <p>The syntheses of the proposed quinoline compounds <b>12aâ€"h</b> (oxazolones) and <b>13aâ€"h (</b>imidazolones) (<a href="#t0001">Table 1</a>) are shown in <a href="#SCH001 SCH002">Schemes 1 and 2</a> and involve two core structural components: (i) 2-methoxyquinolyl-3-carbaldehyde nucleus <b>8aâ€"h</b>, and (ii) 3,4,5-trimethoxyphenyl moiety <b>11</b>. A concise (three-step) synthesis was used for the synthesis of the first core structure, 2-methoxyquinoline-3-carbaldehyde derivatives <b>8aâ€"h,</b> as shown in <a href="#SCH001">Scheme 1</a>. The synthesis was initiated with acetylation of the starting aniline derivatives <b>5aâ€"h</b> using acetic anhydride and glacial acetic acid at 0â€‰Â°C. The produced amides <b>6aâ€"h</b> were subjected to Vilsmeierâ€"Haack reaction to give the corresponding quinoline-3-aldehyde derivatives <b>7aâ€"h</b>. Addition of methoxy substituent to <b>7aâ€"h</b> to give <b>8aâ€"h</b> was achieved through the use of sodium methoxide at 40â€‰Â°C in methanol<a href="#CIT0047"><sup>47</sup></a><sup>,</sup><a href="#CIT0048"><sup>48</sup></a>. The synthesis of the second core 3,4,5-trimethoxyphenyl moiety <b>11</b> started with acylation of the acid <b>9</b> under highly acidic condition using SOCl<sub>2</sub> to give acyl benzotriazole <b>10</b> (<a href="#SCH002">Scheme 2</a>)<a href="#CIT0057"><sup>57</sup></a><sup>,</sup><a href="#CIT0058"><sup>58</sup></a>. Following, treatment of the acyl benzotriazole <b>10</b> with glycine in aqueous acetonitrile gave the acyl glycine <b>11</b>. Condensation of <b>11</b> with the appropriate quinoline aldehydes <b>8aâ€"h</b> in the presence of acetic anhydride and catalytic amount of sodium acetate resulted in the formation of the oxazolones <b>12aâ€"h</b>. Aminolysis of <b>12aâ€"h</b> via condensation reaction with ammonia led to the formation of the imidazolones <b>13aâ€"h</b>. It seems the nucleophilic ammonia attacks the carbonyl group of the oxazolone ring, followed by immediate intramolecular condensation and cyclisation to give the imidazolones <b>13aâ€"h</b>. In summary, two classes of compounds, <b>12aâ€"h</b> (oxazolones) and <b>13aâ€"h</b> (imidazolones) were synthesised and used for further functional and biological studies.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 1.</span></a></div>   <p>Synthetic route for preparation of aldehydes <b>8aâ€"h</b>. Reagents and conditions: (i) Ac<sub>2</sub>O, AcOH, 0â€‰Â°C,1h; (ii) DMF, POCl<sub>3</sub>, 70â€"90â€‰Â°C, 18h; (iii) CH<sub>3</sub>ONa, MeOH, 40â€‰Â°C, 3â€"6h.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 2.</span></a></div>   <p>Synthetic route for preparation of Quinoline targets <b>12aâ€"h</b> and <b>13aâ€"h</b>. Reagents and conditions: (i) SOCl<sub>2</sub>,DCM, r.t; (ii) TEA, MeCN,H<sub>2</sub>O, r.t; (iii) AcONa, AC<sub>2</sub>O, 80â€‰Â°C, 2h; (iv) NH<sub>4</sub>OH, EtOH, reflux, 18h.</p>   </div> <div class="table-wrap_UNKNOWN" id="t0001" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 1.</span> <p>Antiproliferative activity of quinoline analogues against human cancer cell lines (IC<sub>50</sub> [ÂµM]). <span class="inline-graphic" title="inline-graphic" /></p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th rowspan="2" align="left">Compound number</th> <th rowspan="2" align="center">X</th> <th rowspan="2" align="center">R</th> <th colspan="4" align="center">IC<sub>50</sub> value (ÂµM)<sup>a</sup><hr /> </th> </tr> <tr> <th align="center">HL-60</th> <th align="center">MCF-7</th> <th align="center">HCT-116</th> <th align="center">HeLa</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>12a</b></td> <td align="left">O</td> <td align="left">H</td> <td align="char" char=".">3.309â€‰Â±â€‰0.022</td> <td align="left">1.712â€‰Â±â€‰0.040</td> <td align="left">2.012â€‰Â±â€‰0.080</td> <td align="left">2.113â€‰Â±â€‰0.034</td> </tr> <tr> <td align="left"><b>12b</b></td> <td align="left">O</td> <td align="left">6-CH<sub>3</sub></td> <td align="char" char=".">0.197â€‰Â±â€‰0.041</td> <td align="left">0.132â€‰Â±â€‰0.013</td> <td align="left">0.184â€‰Â±â€‰0.007</td> <td align="left">0.117â€‰Â±â€‰0.085</td> </tr> <tr> <td align="left"><b>12c</b></td> <td align="left">O</td> <td align="left">7-CH<sub>3</sub></td> <td align="char" char=".">0.019â€‰Â±â€‰0.059</td> <td align="left">0.010â€‰Â±â€‰0.003</td> <td align="left">0.022â€‰Â±â€‰0.001</td> <td align="left">0.042â€‰Â±â€‰0.001</td> </tr> <tr> <td align="left"><b>12d</b></td> <td align="left">O</td> <td align="left">8-CH<sub>3</sub></td> <td align="char" char=".">0.268â€‰Â±â€‰0.093</td> <td align="left">0.154â€‰Â±â€‰0.071</td> <td align="left">0.191â€‰Â±â€‰0.001</td> <td align="left">0.153â€‰Â±â€‰0.083</td> </tr> <tr> <td align="left"><b>12e</b></td> <td align="left">O</td> <td align="left">6-OCH<sub>3</sub></td> <td align="char" char=".">0.068â€‰Â±â€‰0.034</td> <td align="left">0.056â€‰Â±â€‰0.027</td> <td align="left">0.031â€‰Â±â€‰0.001</td> <td align="left">0.010â€‰Â±â€‰0.004</td> </tr> <tr> <td align="left"><b>12f</b></td> <td align="left">O</td> <td align="left">7-OCH<sub>3</sub></td> <td align="char" char=".">0.352â€‰Â±â€‰0.021</td> <td align="left">0.052â€‰Â±â€‰0.0021</td> <td align="left">0.066â€‰Â±â€‰0.005</td> <td align="left">0.138â€‰Â±â€‰0.026</td> </tr> <tr> <td align="left"><b>12g</b></td> <td align="left">O</td> <td align="left">7-OCH(CH<sub>3</sub>)<sub>2</sub></td> <td align="char" char=".">1.822â€‰Â±â€‰0.640</td> <td align="left">1.507â€‰Â±â€‰0.220</td> <td align="left">7.880â€‰Â±â€‰0.300</td> <td align="left">1.747â€‰Â±â€‰0.500</td> </tr> <tr> <td align="left"><b>12h</b></td> <td align="left">O</td> <td align="left">7-OCH<sub>2</sub>Ph</td> <td align="char" char=".">4.660â€‰Â±â€‰0.260</td> <td align="left">1.932â€‰Â±â€‰0.612</td> <td align="left">1.563â€‰Â±â€‰0.720</td> <td align="left">1.054â€‰Â±â€‰0.840</td> </tr> <tr> <td align="left"><b>13a</b></td> <td align="left">NH</td> <td align="left">H</td> <td align="char" char=".">1.561â€‰Â±â€‰0.055</td> <td align="left">1.033â€‰Â±â€‰0.055</td> <td align="left">8.21â€‰Â±â€‰0.0077</td> <td align="left">1.409â€‰Â±â€‰0.096</td> </tr> <tr> <td align="left"><b>13b</b></td> <td align="left">NH</td> <td align="left">6-CH<sub>3</sub></td> <td align="char" char=".">0.240â€‰Â±â€‰0.012</td> <td align="left">0.063â€‰Â±â€‰0.0011</td> <td align="left">0.173â€‰Â±â€‰0.025</td> <td align="left">0.188â€‰Â±â€‰0.013</td> </tr> <tr> <td align="left"><b>13c</b></td> <td align="left">NH</td> <td align="left">7-CH<sub>3</sub></td> <td align="char" char=".">0.661â€‰Â±â€‰0.026</td> <td align="left">0.223â€‰Â±â€‰0.056</td> <td align="left">0.284â€‰Â±â€‰0.083</td> <td align="left">0.733â€‰Â±â€‰0.091</td> </tr> <tr> <td align="left"><b>13d</b></td> <td align="left">NH</td> <td align="left">8-CH<sub>3</sub></td> <td align="char" char=".">0.096â€‰Â±â€‰0.006</td> <td align="left">0.137â€‰Â±â€‰0.023</td> <td align="left">0.109â€‰Â±â€‰0.011</td> <td align="left">0.126â€‰Â±â€‰0.044</td> </tr> <tr> <td align="left"><b>13e</b></td> <td align="left">NH</td> <td align="left">6-OCH<sub>3</sub></td> <td align="char" char=".">0.272â€‰Â±â€‰0.050</td> <td align="left">0.042â€‰Â±â€‰0.0025</td> <td align="left">0.085â€‰Â±â€‰0.003</td> <td align="left">0.062â€‰Â±â€‰0.003</td> </tr> <tr> <td align="left"><b>13f</b></td> <td align="left">NH</td> <td align="left">7-OCH<sub>3</sub></td> <td align="char" char=".">0.210â€‰Â±â€‰0.098</td> <td align="left">0.092â€‰Â±â€‰0.0062</td> <td align="left">0.187â€‰Â±â€‰0.009</td> <td align="left">0.101â€‰Â±â€‰0.090</td> </tr> <tr> <td align="left"><b>13g</b></td> <td align="left">NH</td> <td align="left">7-OCH(CH<sub>3</sub>)<sub>2</sub></td> <td align="char" char=".">5.114â€‰Â±â€‰0.410</td> <td align="left">5.562â€‰Â±â€‰0.133</td> <td align="left">1.620â€‰Â±â€‰0.950</td> <td align="left">4.439â€‰Â±â€‰0.600</td> </tr> <tr> <td align="left"><b>13h</b></td> <td align="left">NH</td> <td align="left">7-OCH<sub>2</sub>Ph</td> <td align="char" char=".">4.931â€‰Â±â€‰0.260</td> <td align="left">1.695â€‰Â±â€‰0.821</td> <td align="left">2.610â€‰Â±â€‰0.430</td> <td align="left">2.070â€‰Â±â€‰0.390</td> </tr> <tr> <td align="left"><b>CA-4</b></td> <td align="left">â€"</td> <td align="left">â€"</td> <td align="char" char=".">0.076â€‰Â±â€‰0.004</td> <td align="left">0.019â€‰Â±â€‰0.004</td> <td align="left">0.026â€‰Â±â€‰0.001</td> <td align="left">0.064â€‰Â±â€‰0.004</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p><sup>a</sup>IC<sub>50</sub> values are half maximal inhibitory concentrations required to block the growth stimulation of cells. Values represent the mean for three experiments performed in triplicate.</p> </div> </div> </div> </div> <div class="biologicalresultsanddiscussion" title="sec"><span class="label" tagx="label" title="label">3.2.</span><div class="title" tagx="title" title="title">
Biological results and discussion</div> <div class="invitroantiproliferativeactivities" title="sec"><span class="label" tagx="label" title="label">3.2.1.</span><div class="title" tagx="title" title="title"><i>In vitro</i> antiproliferative activities</div> <p>All the synthesised compounds (with CA-4 as a positive reference) were evaluated for their antiproliferative activities using MTT assay with four different cancer cell lines â€" MCF-7 breast adenocarcinoma, HL-60 leukaemia, HCT-116 colorectal carcinoma, and HeLa cervical adenocarcinoma. As shown in <a href="#t0001">Table 1</a>, most of the compounds demonstrated moderate to highly potent antiproliferative activities. In the oxazolone analogues (<b>12a</b>â€"<b>h</b>), compound <b>12a</b> without any substituent on the quinoline ring was the least active when compared with quinoline ring substituted compounds. The relative position of the substituent on the quinoline ring also seemed to be critical for antiproliferative activity. Compound <b>12c</b> with methyl group at the 7-position ring displayed impressive non-selective potency in nanomolar range against HL-60, MCF-7, HCT-116 and HeLa cell lines with IC<sub>50</sub> of 0.019, 0.010, 0.022 and 0.042â€‰ÂµM, which compared to 0.076, 0.019. 0.026 and 0.064â€‰ÂµM for CA-4, respectively. In contrast, both the 6-CH<sub>3</sub> analog (<b>12b</b>) and 8-CH<sub>3</sub> analog (<b>12d</b>) were 3- to 15-fold less active than <b>12c</b>. The nature of the substituents on the quinoline ring of the oxazolone compounds was also found to significantly influence the biological activity. For example, replacement of the methyl group in <b>12b</b> and <b>12c</b> with a stronger electron-releasing methoxy group yielded compounds <b>12e</b> and <b>12f</b>, respectively, which resulted in better antiproliferative activities. The methoxy-containing compound <b>12e</b> was 2.7- to 13-fold more active than the methyl-containing compound <b>12b</b> with the four cancer cell lines (IC<sub>50</sub> of 0.068, 0.056, 0.031 and 0.010â€‰ÂµM in HL-60, MCF-7, HCT-116 and HeLa cancer cell lines, respectively). Compound <b>12f</b> had a similar effect as <b>12c</b> against MCF-7 and HCT-116 cells (0.052 and 0.066â€‰ÂµM, respectively), but with reduction in activity against the other two cell lines, HL-60 and HeLa (0.352 and 0.138â€‰ÂµM, respectively). Introducing larger substituents at the quinoline ring as in <b>12g</b> (7-<i>tert</i>-butyl) and <b>12h</b> (7-benzyloxy) led to a dramatic decrease in activity compared to their corresponding analog <b>12f</b> (7-methoxy). Summarily, adding smaller and/or polar groups to the quinoline ring of the oxazolone resulted in significant improvement in the antiproliferative activity.</p> <p>The imidazolones (Compound <b>13a</b>â€"<b>h)</b> also resulted in impressive antiproliferative activity with IC<sub>50</sub> values ranging from 0.04â€"8.21â€‰ÂµM in all four cell lines. In general, the imidazolones showed similar antiproliferative activities as the oxazolones (<a href="#t0001">Table 1</a>), which could be due to similar electronic effects of the oxazolone and imidazolone rings. Like the oxazolone, lack of substituent on the quinolone ring as in compound <b>13a</b> led to reduction in activity, with IC<sub>50</sub> values of more than 1â€‰ÂµM in all four cell lines, similar to the results obtained with the oxazolone derivative <b>12a</b>. Methyl substitution on the quinoline ring, e.g. 6-CH<sub>3</sub><b>13b</b>, 7-CH<sub>3</sub><b>13c</b> and 8-CH<sub>3</sub><b>13d</b> led to potent activity in submicromolar range in all four cancer cell lines.</p> <p>The position of the methoxy substituent on the quinoline heterocycle also influenced the antiproliferative activity of the compounds against the cancer cell lines. For example, the antiproliferative activity of 6-methoxy-substituted <b>13e</b> was better than its analog 7-methoxy-substituted <b>13f</b> against MCF-7, HCT-116 and HeLa cells with IC<sub>50</sub> values of 0.042, 0.085 and 0.062â€‰ÂµM, which compare to 0.092, 0.187 and 0.101â€‰ÂµM for <b>13f</b>, respectively. However, in HL-60, <b>13e</b> exhibited less antiproliferative activity with IC<sub>50</sub> value of 0.272â€‰ÂµM. In a similar trend as the oxazolone derivatives, bulky substituents on the quinoline ring <b>13g</b> (7-<i>tert</i>-butyl) and <b>13h</b> (7-benzyloxy) resulted in drastic decrease in activity in all four cancer cell lines with 14- to 125-fold loss in potency compared to their corresponding <b>13f</b> (7-methoxy containing) compound.</p> <p>In summary, both oxazolone and imidazolone compounds displayed potent antiproliferative effects, strengthening our hypothesis that nitrogen-containing heterocycles, such as quinoline, are beneficial surrogates for the ring B of CA-4. The different biological activities of the compounds are likely the result of differences in their mode of interaction with the colchicine binding site. Due to its excellent antiproliferative activity, compound <b>12c</b> was studied in more details as described below.</p> </div> <div class="invitroinhibitionoftubulinpolymerisationandcolchicinebinding" title="sec"><span class="label" tagx="label" title="label">3.2.2.</span><div class="title" tagx="title" title="title"><i>In vitro</i> inhibition of tubulin polymerisation and colchicine binding</div> <p>Trimethoxyphenyl (TMP) containing stilbenoid derived compounds, such as colchicine, resveratrol and CA-4 bind to tubulin at the colchicine binding site, resulting in inhibition of microtubule polymerisation<a href="#CIT0059"><sup>59</sup></a><sup>,</sup><a href="#CIT0060"><sup>60</sup></a>. To confirm whether the quinoline compounds similarly target the tubulin-microtubule system, representative quinoline compounds, including four oxazolone analogues (<b>12a</b>, <b>12c</b>, <b>12e</b> and <b>12g</b>) and two imidazolone analogues (<b>13c</b> and <b>13e</b>), as well as the reference compound CA-4, were evaluated for their antitubulin polymerisation activities and the results presented in <a href="#t0002">Table 2</a>. The methyl and methoxy substituted oxazolone compounds <b>12c</b> and <b>12e,</b> respectively strongly inhibited tubulin assembly with IC<sub>50</sub> of 1.21 and 2.26â€‰ÂµM, respectively compared to that of CA-4 (IC<sub>50</sub> of 2.17â€‰ÂµM), while the unsubstituted analogue <b>12a</b> (IC<sub>50</sub> of 13.98â€‰ÂµM) and <i>tert-</i>butyl analog <b>12g</b> (IC<sub>50</sub> of 8.23â€‰ÂµM) were 6- and 4-fold less active than CA-4. The imidazolone compound <b>13e</b> with IC<sub>50</sub> of 1.48â€‰ÂµM also showed very potent tubulin polymerisation inhibition compared to CA-4. The methyl analogue <b>13c</b> was inactive in the tubulin polymerisation assay (IC<sub>50</sub> of 20.29â€‰ÂµM), and is 16-fold less active compared to its corresponding oxazolone derivative <b>12c</b>, which is in agreements with the poor cell growth inhibitory activity of <b>13c</b> compared to <b>12c</b>.</p> <div class="table-wrap_UNKNOWN" id="t0002" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 2.</span> <p>Inhibition of Tubulin Polymerisation and Colchicine Binding by quinoline compounds and CA-4.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th rowspan="3" align="left">Compound number</th> <th align="center">Tubulin assembly<sup>a</sup><hr /> </th> <th colspan="2" align="center">Colchicine binding<sup>b</sup><hr /> </th> </tr> <tr> <th rowspan="2" align="center">IC<sub>50</sub> (ÂµM)</th> <th colspan="2" align="center">%Â± SD <hr /> </th> </tr> <tr> <th align="center">1 ÂµM drug</th> <th align="center">5 ÂµM drug</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>12a</b></td> <td align="char" char=".">13.98</td> <td align="center">nd</td> <td align="center">nd</td> </tr> <tr> <td align="left"><b>12c</b></td> <td align="char" char=".">1.21</td> <td align="center">79â€‰Â±â€‰2</td> <td align="center">87â€‰Â±â€‰1</td> </tr> <tr> <td align="left"><b>12e</b></td> <td align="char" char=".">2.26</td> <td align="center">nd</td> <td align="center">nd</td> </tr> <tr> <td align="left"><b>12g</b></td> <td align="char" char=".">8.23</td> <td align="center">nd</td> <td align="center">nd</td> </tr> <tr> <td align="left"><b>13c</b></td> <td align="char" char=".">20.29</td> <td align="center">nd</td> <td align="center">nd</td> </tr> <tr> <td align="left"><b>13e</b></td> <td align="char" char=".">1.48</td> <td align="center">nd</td> <td align="center">nd</td> </tr> <tr> <td align="left"><b>CA-4</b></td> <td align="char" char=".">2.17</td> <td align="center">86â€‰Â±â€‰0.9</td> <td align="center">97â€‰Â±â€‰2</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p><sup>a</sup>Inhibition of tubulin polymerisation. Tubulin was at 10â€‰ÂµM.</p> </div> <div class="fn-type-" title=""> <p><sup>b</sup>Inhibition of [<sup>3</sup>H] colchicine binding. Tubulin and colchicine were at 1 and 5â€‰ÂµM concentrations, respectively.</p> </div> </div> </div> <p>Compound <b>12c</b> was also examined at two different concentrations (1 and 5â€‰ÂµM) for its ability to compete with colchicine for binding to tubulin using a [<sup>3</sup>H] colchicine binding assay. Compound <b>12c</b> strongly inhibited colchicine binding to tubulin by 79% and 87% at 1 and 5â€‰ÂµM respectively, which compares with 86% and 97% inhibition by CA-4, respectively. These results suggest that compound <b>12c</b> is involved in tubulin polymerisation inhibition through the colchicine-binding site.</p> </div> <div class="cellcycleanalysis" title="sec"><span class="label" tagx="label" title="label">3.2.3.</span><div class="title" tagx="title" title="title">
Cell cycle analysis</div> <p>Induction of cell cycle arrest at G<sub>2</sub>/M phase is strongly accompanied with tubulin polymerisation inhibition. It is well established that CA-4 arrests cell cycle at G<sub>2</sub>M phase<a href="#CIT0061"><sup>61â€"63</sup></a>. To further gain insight into compound <b>12c</b> potent antiproliferative activity, cell cycle analysis of MCF-7 cells was performed at two concentrations of 50â€‰nM and 250â€‰nM and at different time points of 0, 24, 48 and 72â€‰h. <a href="#F0003">Figure 3(A)</a> clearly demonstrates that <b>12c</b> caused a significant arrest in G<sub>2</sub>/M phase and apoptosis in a dose- and time-dependent manner. After 48â€‰h, the percentage of G<sub>2</sub>/M phase arrested cells were 28.4% and 38.3% at 50â€‰nM and 250â€‰nM, respectively compared to 9.2% of untreated cells (<a href="#F0003">Figure 3(B)</a>). Moreover, there was an increase in the number of cells in G<sub>2</sub>/M phase after 72â€‰h (33.0% and 40.8% at 50â€‰nM and 250â€‰nM, respectively) with a concomitant decrease of cells in G<sub>0</sub>/G<sub>1</sub> phase (40.3% and 29.8% at 50â€‰nM and 250â€‰nM, respectively) compared to the control (57.3%). In a comparable finding, CA-4 (50â€‰nM) also significantly arrested G<sub>2</sub>/M phase at 24, 48 and 72â€‰h (40.3%, 43.8% and 47.7%, respectively). Accordingly, a concomitant decrease of MCF-7 cells was detected in G0 phase (<a href="#F0003">Figure 3(C)</a>). Furthermore, compound <b>12c</b> induced a gradual increase in apoptosis (16.2%, 23.4% and 32.7%) at 250â€‰nM as the proportion of cells in the sub-G1 phase increased at 24, 48 and 72â€‰h, respectively compared to untreated cells (1.5%) (<a href="#F0003">Figure 3(D)</a>). Similarly, 23.5%, 31.1% and 37.4% increase in apoptosis was observed for CA-4 at 24, 48 and 72â€‰h, respectively. These findings are in agreement with previously reported for a series of related quinoline analogues, which significantly induced apoptosis and G<sub>2</sub>/M cycle arrest in MCF-7 cells<a href="#CIT0023"><sup>23</sup></a><sup>,</sup><a href="#CIT0042"><sup>42</sup></a><sup>,</sup><a href="#CIT0046"><sup>46</sup></a><sup>,</sup><a href="#CIT0064"><sup>64</sup></a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 3.</span></a></div>   <p>(A) Effect of compound <b>12c</b> on the cell cycle and apoptosis in MCF-7 cells. Cells were treated with either vehicle [0.1% ethanol (v/v)], CA-4 (50â€‰nM), <b>12c</b> (50â€‰nM and 250â€‰nM) for 24â€‰h, 48â€‰h and 72â€‰h. Cells were then fixed, stained with PI, and analysed by flow cytometry. Cell cycle analysis was performed on histograms of gated counts per DNA area (FL2-A). The number of cells with (B) 4â€‰N (G<sub>2</sub>/M), (C) 2â€‰N(G<sub>0</sub>G<sub>1</sub>), and (D) &amp;lt;2â€‰N (sub-G<sub>1</sub>) DNA content was determined with CellQuest software. Values represent the meanâ€‰Â±â€‰SEM for three independent experiments. Statistical analysis was performed using two-way ANOVA (*<i>p</i>â€‰<div class="â€‰0.05;_UNKNOWN">
pâ€‰<div class="â€‰0.01;_UNKNOWN">
pâ€‰<div class="â€‰0.001)._UNKNOWN" /></div></div></p>   </div> </div> <div class="cellapoptosis" title="sec"><span class="label" tagx="label" title="label">3.2.4.</span><div class="title" tagx="title" title="title">
Cell apoptosis</div> <p>We investigated whether cell death induced by compound <b>12c</b> treatment was related to apoptosis using the Annexin-V/PI double staining flow cytometric assay (<a href="#F0004">Figure 4(A,B)</a>). MCF-7 cells were treated with three different concentrations (0, 50 and 250â€‰nM) of compound <b>12c</b> at different time points (24, 48 and 72â€‰h). Compound <b>12c</b> caused a significant accumulation of annexine-V positive cells and induced both early and late apoptosis in a dose- and time-dependent manner compared to the untreated cells. As shown in <a href="#F0004">Figure 4(B)</a>, when the cells were treated with <b>12c (</b>0 and 250â€‰nM) or CA-4 (50â€‰nM) for 48â€‰h, the percentage of Annexin V-staining positive cells significantly increased from 1% in untreated cells to 15%, 21% and 29% respectively. The percentage of early and late apoptotic cells in the presence of <b>12c</b> increased after 72â€‰h to 17.6% and 29.3% at 1 and 5â€‰ÂµM respectively when compared to the untreated cells (2%). Based on the cell cycle arrest and apoptosis findings (<a href="#F0003">Figure 3(Bâ€"D)</a>), it appears that compound <b>12c</b> could efficiently induce apoptosis cell death in MCF-7 cells in a dose- and time-dependent manner.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 4.</span></a></div>   <p>(A) Effect of compound <b>12c</b> at different time points on apoptosis in MCF-7 cells analysed by flow cytometry after double staining of the cells with Annexin-V-FITC and PI. MCF-7 cells treated with 50 and 250â€‰nM of compound <b>12c</b> and 50â€‰nM of CA-4 for 24â€‰h, 48â€‰h and 72â€‰h and collected and processed for analysis. (B) Quantitative analysis of apoptosis. Values represent the meanâ€‰Â±â€‰SEM for three independent experiments. Statistical analysis was performed using two-way ANOVA (*<i>p</i>â€‰<div class="â€‰0.05**_UNKNOWN">
pâ€‰<div class="â€‰0.01;_UNKNOWN">
pâ€‰<div class="â€‰0.001)._UNKNOWN" /></div></div></p>   </div> </div> <div class="assessmentoftoxicitytonon-tumorigenichumancells" title="sec"><span class="label" tagx="label" title="label">3.2.5.</span><div class="title" tagx="title" title="title">
Assessment of toxicity to non-tumorigenic human cells</div> <p>To assess the cytotoxicity and selectivity of <b>12c</b> towards cancer cells, normal epithelial breast MCF-10A cell viability study was carried out. As shown in <a href="#F0005">Figure 5(A)</a>, the IC<sub>50</sub> value of <b>12c</b> was more than 50â€‰ÂµM in MCF-10A cells, which was significantly higher than the IC<sub>50</sub> values of 19, 10, 22 and 42â€‰nM in MCF-7, HL-60, HCT-116 and HeLa cancer cell lines, respectively. Remarkably, <b>12c</b> was found to be less toxic in normal MCF-10A (IC<sub>50</sub> &amp;gt;50â€‰ÂµM) when compared to CA-4 (IC<sub>50</sub> = 6.1â€‰ÂµM) (<a href="#F0005">Figure 5(B)</a>), suggesting <b>12c</b> to have better selective toxicity against cancer cells.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 5.</span></a></div>   <p>Dose response curve for (A) Compound <b>12c</b> and (B) CA-4 on the proliferation of breast cancer MCF-7 and normal breast MCF-10A cells. Cells were grown in 96-well plates and treated with serial concentrations of compound <b>12c or</b> CA-4 for 72â€‰h. Cell viability was expressed as percentage of vehicle control [ethanol 1% (v/v)] treated cells and was measured by MTT assay (average of three independent experiments).</p>   </div> </div> <div class="expressionoftheapoptoticproteinsinmcf-7celllines" title="sec"><span class="label" tagx="label" title="label">3.2.6.</span><div class="title" tagx="title" title="title">
Expression of the apoptotic proteins in MCF-7 cell lines</div> <p>The previous data clearly demonstrate that <b>12c</b> is an effective anti-mitotic quinoline compound in MCF-7 cell lines. Herein, the effect of <b>12c</b> on the expression of apoptosis pathway markers, Bcl-2 anti-apoptotic protein and Bax pro-apoptotic protein was investigated. MCF-7 cells treated with <b>12c</b> at 250â€‰nM for 48â€‰h decreased the expression level of the anti-apoptotic protein Bcl-2, and correspondingly up-regulated the expression of the pro-apoptotic protein Bax (<a href="#F0006">Figure 6(A,B)</a>).</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 6.</span></a></div>   <p>Effect of compound <b>12c</b> on the expression (A) anti-apoptotic protein Bcl2, (B) pro-apoptotic protein BAX and (C) Caspase 9 in MCF-7 cells.</p>   </div> <p>Activation of caspases initiates apoptosis, and in particular caspase-9 is considered an important effector caspase responsible for programmed cell death apoptosis activated by CA-4<a href="#CIT0061"><sup>61</sup></a><sup>,</sup><a href="#CIT0065"><sup>65</sup></a><sup>,</sup><a href="#CIT0066"><sup>66</sup></a>. The amount of activated caspase-9 was examined in MCF-7 cells treated with <b>12c</b>. As observed from <a href="#F0006">Figure 6(C)</a>, compound <b>12c</b> at 50 and 250â€‰nM produced about 8- and 16-fold increases in caspase-9 activation respectively when compared to 14-fold for CA-4 (50â€‰nM). This finding confirms that compound <b>12c</b> like CA-4 enhanced the rate of apoptosis in MCF-7 cell through caspase-9 activation.</p> </div> <div class="inhibitionofcolonyformation" title="sec"><span class="label" tagx="label" title="label">3.2.7.</span><div class="title" tagx="title" title="title">
Inhibition of colony formation</div> <p>Colony formation assay is one of the effective techniques for the determination of long-term cell proliferation upon anticancer drug exposure. The inhibitory potential of <b>12c</b> on MCF-7 cells colony formation is displayed in <a href="#F0007">Figure 7</a>. Compound <b>12c</b> suppressed the clonogenic formation potential of MCF-7 cells in a dose dependent manner when compared to CA-4.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 7.</span></a></div>   <p>(A) Inhibition of colony formation in MCF-7 cells by 50 and 250â€‰nM of compound <b>12c</b> and 50â€‰nM of CA-4 for 48â€‰h. (B) Quantitative analysis of colony formation. .</p>   </div> </div> <div class="woundhealingassay" title="sec"><span class="label" tagx="label" title="label">3.2.8.</span><div class="title" tagx="title" title="title">
Wound healing assay</div> <p>Migration and motility of cancer cells are considered as critical factors in tumour progression and metastasis<a href="#CIT0067"><sup>67</sup></a><sup>,</sup><a href="#CIT0068"><sup>68</sup></a>. In order to investigate the effect of compound <b>12c</b> on the migration of MCF-7, wound healing assay was performed. As illustrated in <a href="#F0008">Figure 8(A,B)</a>, the untreated cells migrated to the scraped area while in <b>12c</b>-treated wells, cell migration was significantly inhibited in a dose-dependent manner. This significant difference in the wound area confirms that <b>12c</b> suppressed MCF-7 cell migration, an important event in tumour metastasis.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 8.</span></a></div>   <p>(A) Inhibition of the migration of MCF-7 cells treated with compound <b>12c</b> for 48â€‰h in the wound healing assay. (B) Quantitative analysis of wound closure rate and was calculated as meanâ€‰Â±â€‰SEM for three independent experiments. Statistical analysis was performed using one-way ANOVA-Bonferroni post-hoc test (***<i>p</i>â€‰<div class="â€‰0.001)._UNKNOWN" /></p>   </div> </div> <div class="mitochondrialmembranepotential" title="sec"><span class="label" tagx="label" title="label">3.2.9.</span><div class="title" tagx="title" title="title">
Mitochondrial membrane potential</div> <p>Mitochondria membrane potential plays a crucial role in the propagation of apoptosis. Specifically, loss of mitochondrial membrane potential Î"Ïˆ<sub>mt</sub> (MMP) is characteristic of early stage of apoptosis<a href="#CIT0069"><sup>69â€"71</sup></a>. To confirm whether compound <b>12c</b> could decrease the MMP of MCF-7 cancer cells, MMP was monitored by the fluorescence of the dye DiOC2(3). MCF-7 cells treated with <b>12c</b> at 50 and 250â€‰nM exhibited significant decrease in MMP in a dose- and time-dependant manner (<a href="#F0009">Figure 9(A)</a>). This depletion in MMP was associated with an increase of annexin-V positive early apoptotic cells. Maximum decrease in MCF-7 MMP was detected after 24â€‰h treatment with <b>12c</b> in which the percentage of apoptotic cells increased from 1.1% to 24.9% and 31.3% at 50 and 250â€‰nM, respectively (<a href="#F0009">Figure 9(B)</a>). This indicates that compound <b>12c</b> induces mitochondrial dysfunction in MCF-7, which eventually triggered apoptotic cell death. These results are in agreement with previously reported CA-4 analogues study that were shown to cause apoptosis through the mitochondrial pathway<a href="#CIT0068"><sup>68</sup></a><sup>,</sup><a href="#CIT0072"><sup>72</sup></a><sup>,</sup><a href="#CIT0073"><sup>73</sup></a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 9.</span></a></div>   <p>Assessment of mitochondrial membrane potential (Î"Ïˆ<sub>mt</sub>) after treatment of MCF-7 cells with <b>12c</b>. Cells were treated with indicated concentration of compound <b>12c</b> for 6, 12 and 24â€‰h and then stained with fluorescent DiOC2(3) for analysis of mitochondrial potential. Cells were then analysed by flow cytometry as described in the experimental section. Data are presented as meanâ€‰Â±â€‰SEM of three independent experiments. Statistical analysis was performed using two-way ANOVA (**<i>p</i>â€‰<div class="â€‰0.01;_UNKNOWN">
pâ€‰<div class="â€‰0.001)._UNKNOWN" /></div></p>   </div> </div> <div class="intracellularreactiveoxygenspecies(ros)production" title="sec"><span class="label" tagx="label" title="label">3.2.10.</span><div class="title" tagx="title" title="title">
Intracellular reactive oxygen species (ROS) production</div> <p>The dissipation of mitochondrial potential is strongly associated with mitochondrial production of reactive oxygen species (ROS)<a href="#CIT0071"><sup>71</sup></a><sup>,</sup><a href="#CIT0073"><sup>73</sup></a>. The production of ROS after <b>12c</b> treatment at 50 and 250â€‰nM, as well as CA-4 (50â€‰nM) with hydrogen peroxide H<sub>2</sub>O<sub>2</sub> was followed with 2,7â€"dichlorofluorescin diacetate (H<sub>2</sub>-DCFDA). As shown in <a href="#F0010">Figure 10</a>, after 24â€‰h of <b>12c</b> treatment, the levels of ROS in MCF-7 cells were 22.7 and 26.6% at 50 and 250â€‰nM, respectively. The level in untreated MCF-7 cells was 1.0%, while it increased only to 18.3% in CA-4-treated cells. This result along with the significant loss of mitochondrial membrane potential above clearly suggests that compound <b>12c</b> induced apoptosis via the mitochondrial pathway.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 10.</span></a></div>   <p>Effect of compound <b>12c</b> at different time points on ROS production in MCF-7 cells. MCF-7 cells treated without and with 50 and 250â€‰nM of compound <b>12c</b> and 50â€‰nM of CA-4 and 100â€‰ÂµM H<sub>2</sub>O<sub>2</sub> for 6â€‰h, 12â€‰h and 24â€‰h. Cells were incubated with DCFDA (25â€‰ÂµM) dye for 1â€‰h at 37â€‰Â°C in dark. Fluorescence intensity per cell at 525â€‰nm was calculated as meanâ€‰Â±â€‰SEM for three independent experiments. Statistical analysis was performed using two-way ANOVA (***<i>p</i>â€‰<div class="â€‰0.001)._UNKNOWN" /></p>   </div> </div> </div> </div> <div class="conclusions" title="conclusions"><span class="label" tagx="label" title="label">4.</span><div class="title" tagx="title" title="title">
Conclusion</div> <p>In this study, we designed, synthesised and evaluated two classes of novel quinoline compounds combretastatin A-4 derivatives as potential inhibitors of tubulin polymerisation. Several other studies have also reported derivatisation of the CA-4 pharmacophore with varying success<a href="#CIT0027"><sup>27â€"32</sup></a>. Unlike the previous compounds, we for the first time introduced a chalcone system, including oxazolones and imidazolones to the <i>cis</i> bond of CA-4 to give more rigidity to the required active conformation. The chalcone system is well known for its anticancer activities. Our design also kept the essential natural trimethoxyphenyl pharmacophore (found in CA-4), while varying the electronic substituents effect on the quinolyl moiety (ring B) that were expected to enhance the potency of the compounds. Most of the compounds showed significant and, in some instances, comparable antiproliferative activities against different cancer cell lines as the previously studied combretastatin A-4 compound, CA-4. One of the most promising compound <b>12c</b> showed potent anti-proliferative activities against HL-60, MCF-7, HCT-116 and HeLA cancer cell lines with IC<sub>50</sub> values of 0.019, 0.010, 0.022 and 0.042â€‰ÂµM, respectively, and simultaneously low cytotoxicity towards MCF-10A non-cancer cells. The microtubule polymerisation inhibitory effect of <b>12c</b> was confirmed with an <i>inÂ vitro</i> tubulin polymerisation and colchicine inhibition assays. Compound <b>12c</b> effectively block the G<sub>2</sub>/M phase at the cell cycle and induce MCF-7 cell apoptosis together with significant change of Bax/Bcl expression ratio indicating involvement of mitochondrial apoptosis pathway. Further cellular mechanistic studies confirmed that <b>12c</b> inhibited MCF-7 cell migration and colony formation. In conclusion, these results highlight our novel quinoline compounds and particularly <b>12c</b> as promising anti-tubulin agent for the treatment of MCF-7 breast cancer cells. Moreover, the results point to a direction for rational development of potent tubulin polymerisation inhibitors for the treatment of cancer.</p> </div> </div> <div class="back" title="back"> <div class="ack" title="ack"> <div class="title" tagx="title" title="title">
Acknowledgements</div> <p>The authors gratefully acknowledge DSR technical and financial support.</p> </div> <div class="COI-statement" title="COI-statement"> <div class="title" tagx="title" title="title">
Disclosure statement</div> <p>The authors declare no competing interests.</p> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="CIT0001" /><span class="label" tagx="label" title="label">1</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bray</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ferlay</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Soerjomataram</span><span class="given-names" tagx="given-names" title="given-names">I</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries</span>. <span class="source" tagx="source" title="source">CA Cancer J Clin</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">68</span>:<span class="fpage" tagx="fpage" title="fpage">394</span>â€"<span class="lpage" tagx="lpage" title="lpage">424</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30207593">30207593</a></span></span></li> <li tag="ref"><a name="CIT0002" /><span class="label" tagx="label" title="label">2</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Decosterd</span><span class="given-names" tagx="given-names" title="given-names">LA</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Widmer</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zaman</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Therapeutic drug monitoring of targeted anticancer therapy</span>. <span class="source" tagx="source" title="source">Biomark Med</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">9</span>:<span class="fpage" tagx="fpage" title="fpage">887</span>â€"<span class="lpage" tagx="lpage" title="lpage">93</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26333311">26333311</a></span></span></li> <li tag="ref"><a name="CIT0003" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">La Regina</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Coluccia</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Naccarato</span><span class="given-names" tagx="given-names" title="given-names">V</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Silvestri</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Towards modern anticancer agents that interact with tubulin</span>. <span class="source" tagx="source" title="source">Eur J Pharm Sci</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">131</span>:<span class="fpage" tagx="fpage" title="fpage">58</span>â€"<span class="lpage" tagx="lpage" title="lpage">68</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30690185">30690185</a></span></span></li> <li tag="ref"><a name="CIT0004" /><span class="label" tagx="label" title="label">4</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Stec-Martyna</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ponassi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Miele</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Structural comparison of the interaction of tubulin with various ligands affecting microtubule dynamics</span>. <span class="source" tagx="source" title="source">Curr Cancer Drug Targets</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">12</span>:<span class="fpage" tagx="fpage" title="fpage">658</span>â€"<span class="lpage" tagx="lpage" title="lpage">66</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22385515">22385515</a></span></span></li> <li tag="ref"><a name="CIT0005" /><span class="label" tagx="label" title="label">5</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Devi Tangutur</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kumar</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Vamsi Krishna</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kantevari</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Microtubule targeting agents as cancer chemotherapeutics: An overview of molecular hybrids as stabilizing and destabilizing agents</span>. <span class="source" tagx="source" title="source">Curr Top Med Chem</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">17</span>:<span class="fpage" tagx="fpage" title="fpage">2523</span>â€"<span class="lpage" tagx="lpage" title="lpage">37</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28056738">28056738</a></span></span></li> <li tag="ref"><a name="CIT0006" /><span class="label" tagx="label" title="label">6</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kavallaris</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Microtubules and resistance to tubulin-binding agents</span>. <span class="source" tagx="source" title="source">Nat Rev Cancer</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">10</span>:<span class="fpage" tagx="fpage" title="fpage">194</span>â€"<span class="lpage" tagx="lpage" title="lpage">204</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20147901">20147901</a></span></span></li> <li tag="ref"><a name="CIT0007" /><span class="label" tagx="label" title="label">7</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Coulup</span><span class="given-names" tagx="given-names" title="given-names">SK</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Georg</span><span class="given-names" tagx="given-names" title="given-names">GI.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Revisiting microtubule targeting agents: Î‘-tubulin and the pironetin binding site as unexplored targets for cancer therapeutics</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">29</span>:<span class="fpage" tagx="fpage" title="fpage">1865</span>â€"<span class="lpage" tagx="lpage" title="lpage">73</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31130264">31130264</a></span></span></li> <li tag="ref"><a name="CIT0008" /><span class="label" tagx="label" title="label">8</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Vindya</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Sharma</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Yadav</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ethiraj</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Tubulins â€" the target for anticancer therapy</span>. <span class="source" tagx="source" title="source">Curr Top Med Chem</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">15</span>:<span class="fpage" tagx="fpage" title="fpage">73</span>â€"<span class="lpage" tagx="lpage" title="lpage">82</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25579568">25579568</a></span></span></li> <li tag="ref"><a name="CIT0009" /><span class="label" tagx="label" title="label">9</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Dumontet</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Jordan</span><span class="given-names" tagx="given-names" title="given-names">MA.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Microtubule-binding agents: a dynamic field of cancer therapeutics</span>. <span class="source" tagx="source" title="source">Nat Rev Drug Discov</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">9</span>:<span class="fpage" tagx="fpage" title="fpage">790</span>â€"<span class="lpage" tagx="lpage" title="lpage">803</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20885410">20885410</a></span></span></li> <li tag="ref"><a name="CIT0010" /><span class="label" tagx="label" title="label">10</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Sharma</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kaur</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Budhiraja</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Chalcone based azacarboline analogues as novel antitubulin agents: design, synthesis, biological evaluation and molecular modelling studies</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">85</span>:<span class="fpage" tagx="fpage" title="fpage">648</span>â€"<span class="lpage" tagx="lpage" title="lpage">60</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25128667">25128667</a></span></span></li> <li tag="ref"><a name="CIT0011" /><span class="label" tagx="label" title="label">11</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kaur</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kaur</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gill</span><span class="given-names" tagx="given-names" title="given-names">RK</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Soni</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Recent developments in tubulin polymerization inhibitors: an overview</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">87</span>:<span class="fpage" tagx="fpage" title="fpage">89</span>â€"<span class="lpage" tagx="lpage" title="lpage">124</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25240869">25240869</a></span></span></li> <li tag="ref"><a name="CIT0012" /><span class="label" tagx="label" title="label">12</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bukhari</span><span class="given-names" tagx="given-names" title="given-names">SNA</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kumar</span><span class="given-names" tagx="given-names" title="given-names">GB</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Revankar</span><span class="given-names" tagx="given-names" title="given-names">HM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Qin</span><span class="given-names" tagx="given-names" title="given-names">HL.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Development of combretastatins as potent tubulin polymerization inhibitors</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">72</span>:<span class="fpage" tagx="fpage" title="fpage">130</span>â€"<span class="lpage" tagx="lpage" title="lpage">47</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28460355">28460355</a></span></span></li> <li tag="ref"><a name="CIT0013" /><span class="label" tagx="label" title="label">13</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Naumova</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Å achl</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Regulation of cell death by mitochondrial transport systems of calcium and bcl-2 proteins</span>. <span class="source" tagx="source" title="source">Membranes</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">10</span>:<span class="fpage" tagx="fpage" title="fpage">299</span>.</span></li> <li tag="ref"><a name="CIT0014" /><span class="label" tagx="label" title="label">14</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Thomas</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gopalakrishnan</span><span class="given-names" tagx="given-names" title="given-names">V</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Hegde</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A novel resveratrol based tubulin inhibitor induces mitotic arrest and activates apoptosis in cancer cells</span>. <span class="source" tagx="source" title="source">Sci Rep</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">6</span>:<span class="fpage" tagx="fpage" title="fpage">34653</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27748367">27748367</a></span></span></li> <li tag="ref"><a name="CIT0015" /><span class="label" tagx="label" title="label">15</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Naaz</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Haider</span><span class="given-names" tagx="given-names" title="given-names">MR</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Shafi</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Yar</span><span class="given-names" tagx="given-names" title="given-names">MS.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Anti-tubulin agents of natural origin: targeting taxol, vinca, and colchicine binding domains</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">171</span>:<span class="fpage" tagx="fpage" title="fpage">310</span>â€"<span class="lpage" tagx="lpage" title="lpage">31</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30953881">30953881</a></span></span></li> <li tag="ref"><a name="CIT0016" /><span class="label" tagx="label" title="label">16</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Cao</span><span class="given-names" tagx="given-names" title="given-names">YN</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zheng</span><span class="given-names" tagx="given-names" title="given-names">LL</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Recent advances in microtubule-stabilizing agents</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">143</span>:<span class="fpage" tagx="fpage" title="fpage">806</span>â€"<span class="lpage" tagx="lpage" title="lpage">28</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29223097">29223097</a></span></span></li> <li tag="ref"><a name="CIT0017" /><span class="label" tagx="label" title="label">17</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Cragg</span><span class="given-names" tagx="given-names" title="given-names">GM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kingston</span><span class="given-names" tagx="given-names" title="given-names">DG</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Newman</span><span class="given-names" tagx="given-names" title="given-names">DJ.</span></span></span><span class="source" tagx="source" title="source">Anticancer agents from natural products</span>. <span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Boca Raton (FL)</span>: <span class="publisher-name" tagx="publisher-name" title="publisher-name">CRC press</span>; <span class="year" tagx="year" title="year">2012</span>.</span></li> <li tag="ref"><a name="CIT0018" /><span class="label" tagx="label" title="label">18</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gupta</span><span class="given-names" tagx="given-names" title="given-names">SK</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Singh</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ali</span><span class="given-names" tagx="given-names" title="given-names">V</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Verma</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Role of membrane-embedded drug efflux abc transporters in the cancer chemotherapy</span>. <span class="source" tagx="source" title="source">Oncol Rev</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">14</span>:<span class="fpage" tagx="fpage" title="fpage">448</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32676170">32676170</a></span></span></li> <li tag="ref"><a name="CIT0019" /><span class="label" tagx="label" title="label">19</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Arnst</span><span class="given-names" tagx="given-names" title="given-names">KE</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lei</span><span class="given-names" tagx="given-names" title="given-names">ZN</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Colchicine binding site agent dj95 overcomes drug resistance and exhibits antitumor efficacy</span>. <span class="source" tagx="source" title="source">Mol Pharmacol</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">96</span>:<span class="fpage" tagx="fpage" title="fpage">73</span>â€"<span class="lpage" tagx="lpage" title="lpage">89</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31043459">31043459</a></span></span></li> <li tag="ref"><a name="CIT0020" /><span class="label" tagx="label" title="label">20</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zweifel</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Jayson</span><span class="given-names" tagx="given-names" title="given-names">GC</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Reed</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Phase ii trial of combretastatin a4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</span>. <span class="source" tagx="source" title="source">Ann Oncol</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">2036</span>â€"<span class="lpage" tagx="lpage" title="lpage">41</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21273348">21273348</a></span></span></li> <li tag="ref"><a name="CIT0021" /><span class="label" tagx="label" title="label">21</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Sun</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures</span>. <span class="source" tagx="source" title="source">Future Med Chem</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">9</span>:<span class="fpage" tagx="fpage" title="fpage">1765</span>â€"<span class="lpage" tagx="lpage" title="lpage">94</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28929799">28929799</a></span></span></li> <li tag="ref"><a name="CIT0022" /><span class="label" tagx="label" title="label">22</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kamath</span><span class="given-names" tagx="given-names" title="given-names">PR</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Sunil</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ajees</span><span class="given-names" tagx="given-names" title="given-names">AA.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis of indoleâ€"quinolineâ€"oxadiazoles: their anticancer potential and computational tubulin binding studies</span>. <span class="source" tagx="source" title="source">Res Chem Intermed</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">42</span>:<span class="fpage" tagx="fpage" title="fpage">5899</span>â€"<span class="lpage" tagx="lpage" title="lpage">914</span>.</span></li> <li tag="ref"><a name="CIT0023" /><span class="label" tagx="label" title="label">23</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Khelifi</span><span class="given-names" tagx="given-names" title="given-names">I</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Naret</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Renko</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and anticancer properties of isocombretaquinolines as potent tubulin assembly inhibitors</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">127</span>:<span class="fpage" tagx="fpage" title="fpage">1025</span>â€"<span class="lpage" tagx="lpage" title="lpage">34</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28166995">28166995</a></span></span></li> <li tag="ref"><a name="CIT0024" /><span class="label" tagx="label" title="label">24</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Seligmann</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Twelves</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Tubulin: an example of targeted chemotherapy</span>. <span class="source" tagx="source" title="source">Future Med Chem</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">5</span>:<span class="fpage" tagx="fpage" title="fpage">339</span>â€"<span class="lpage" tagx="lpage" title="lpage">52</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23464522">23464522</a></span></span></li> <li tag="ref"><a name="CIT0025" /><span class="label" tagx="label" title="label">25</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">PiekuÅ›-SÅ‚omka</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mikstacka</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ronowicz</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Sobiak</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Hybrid cis-stilbene molecules: novel anticancer agents</span>. <span class="source" tagx="source" title="source">Int J Mol Sci</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">20</span>:<span class="fpage" tagx="fpage" title="fpage">1300</span>.</span></li> <li tag="ref"><a name="CIT0026" /><span class="label" tagx="label" title="label">26</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Haider</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Rahaman</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Yar</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kamal</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018)</span>. <span class="source" tagx="source" title="source">Expert Opin Ther Pat</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">29</span>:<span class="fpage" tagx="fpage" title="fpage">623</span>â€"<span class="lpage" tagx="lpage" title="lpage">41</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31353978">31353978</a></span></span></li> <li tag="ref"><a name="CIT0027" /><span class="label" tagx="label" title="label">27</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Das</span><span class="given-names" tagx="given-names" title="given-names">BC</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Tang</span><span class="given-names" tagx="given-names" title="given-names">XY</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Rogler</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Evans</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Design and synthesis of 3,5-disubstituted boron-containing 1,2,4-oxadiazoles as potential combretastatin a-4 (ca-4) analogs</span>. <span class="source" tagx="source" title="source">Tetrahedron Lett</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">53</span>:<span class="fpage" tagx="fpage" title="fpage">3947</span>â€"<span class="lpage" tagx="lpage" title="lpage">50</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24039307">24039307</a></span></span></li> <li tag="ref"><a name="CIT0028" /><span class="label" tagx="label" title="label">28</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Biersack</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Effenberger</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Schobert</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ocker</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Oxazole-bridged combretastatin a analogues with improved anticancer properties</span>. <span class="source" tagx="source" title="source">ChemMedChem</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">5</span>:<span class="fpage" tagx="fpage" title="fpage">420</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20112324">20112324</a></span></span></li> <li tag="ref"><a name="CIT0029" /><span class="label" tagx="label" title="label">29</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mahal</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Biersack</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Schruefer</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Combretastatin a-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">118</span>:<span class="fpage" tagx="fpage" title="fpage">9</span>â€"<span class="lpage" tagx="lpage" title="lpage">20</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27116710">27116710</a></span></span></li> <li tag="ref"><a name="CIT0030" /><span class="label" tagx="label" title="label">30</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Biernacki</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">DaÅ›ko</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ciupak</span><span class="given-names" tagx="given-names" title="given-names">O</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel 1,2,4-oxadiazole derivatives in drug discovery</span>. <span class="source" tagx="source" title="source">Pharmaceuticals (Basel)</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">13</span>:<span class="fpage" tagx="fpage" title="fpage">111</span>.</span></li> <li tag="ref"><a name="CIT0031" /><span class="label" tagx="label" title="label">31</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Schmitt</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gosch</span><span class="given-names" tagx="given-names" title="given-names">LC</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Dittmer</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Oxazole-bridged combretastatin A-4 derivatives with tethered hydroxamic acids: structure(-)activity relations of new inhibitors of hdac and/or tubulin function</span>. <span class="source" tagx="source" title="source">Int J Mol Sci</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">20</span>:<span class="fpage" tagx="fpage" title="fpage">283</span>.</span></li> <li tag="ref"><a name="CIT0032" /><span class="label" tagx="label" title="label">32</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Quan</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis, and biological evaluation of 1-substituted-2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">184</span>:<span class="fpage" tagx="fpage" title="fpage">111732</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31610372">31610372</a></span></span></li> <li tag="ref"><a name="CIT0033" /><span class="label" tagx="label" title="label">33</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ibrahim</span><span class="given-names" tagx="given-names" title="given-names">TS</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Hawwas</span><span class="given-names" tagx="given-names" title="given-names">MM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Malebari</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Potent quinoline-containing combretastatin a-4 analogues: design, synthesis, antiproliferative, and anti-tubulin activity</span>. <span class="source" tagx="source" title="source">Pharmaceuticals (Basel)</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">13</span>:<span class="fpage" tagx="fpage" title="fpage">393</span>.</span></li> <li tag="ref"><a name="CIT0034" /><span class="label" tagx="label" title="label">34</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Jian</span><span class="given-names" tagx="given-names" title="given-names">XE</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Jiang</span><span class="given-names" tagx="given-names" title="given-names">CS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of novel pyrazolo[3,4-b]pyridines as cis-restricted combretastatin a-4 analogues</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">30</span>:<span class="fpage" tagx="fpage" title="fpage">127025</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32063430">32063430</a></span></span></li> <li tag="ref"><a name="CIT0035" /><span class="label" tagx="label" title="label">35</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Jian</span><span class="given-names" tagx="given-names" title="given-names">XE</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Diao</span><span class="given-names" tagx="given-names" title="given-names">PC</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, and biological evaluation of 3,6-diaryl-[1,2,4]triazolo[4,3-a]pyridine analogues as new potent tubulin polymerization inhibitors</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">204</span>:<span class="fpage" tagx="fpage" title="fpage">112625</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32717486">32717486</a></span></span></li> <li tag="ref"><a name="CIT0036" /><span class="label" tagx="label" title="label">36</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ma</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Huo</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Development of triazolothiadiazine derivatives as highly potent tubulin polymerization inhibitors: structure-activity relationship, inÂ vitro and inÂ vivo study</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">208</span>:<span class="fpage" tagx="fpage" title="fpage">112847</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/33022479">33022479</a></span></span></li> <li tag="ref"><a name="CIT0037" /><span class="label" tagx="label" title="label">37</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kaur</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Jain</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Reddy</span><span class="given-names" tagx="given-names" title="given-names">RP</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Jain</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Quinolines and structurally related heterocycles as antimalarials</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">45</span>:<span class="fpage" tagx="fpage" title="fpage">3245</span>â€"<span class="lpage" tagx="lpage" title="lpage">64</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20466465">20466465</a></span></span></li> <li tag="ref"><a name="CIT0038" /><span class="label" tagx="label" title="label">38</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Maurya</span><span class="given-names" tagx="given-names" title="given-names">SS</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Khan</span><span class="given-names" tagx="given-names" title="given-names">SI</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bahuguna</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, antimalarial activity, heme binding and docking studies of n-substituted 4-aminoquinoline-pyrimidine molecular hybrids</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">129</span>:<span class="fpage" tagx="fpage" title="fpage">175</span>â€"<span class="lpage" tagx="lpage" title="lpage">85</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28222317">28222317</a></span></span></li> <li tag="ref"><a name="CIT0039" /><span class="label" tagx="label" title="label">39</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Vaibhav</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Dinesh Kumar</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Rina</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Synthetic methods of quinoline derivatives as potent anticancer agents</span>. <span class="source" tagx="source" title="source">Mini-Rev Med Chem</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">17</span>:<span class="fpage" tagx="fpage" title="fpage">1557</span>â€"<span class="lpage" tagx="lpage" title="lpage">72</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28494729">28494729</a></span></span></li> <li tag="ref"><a name="CIT0040" /><span class="label" tagx="label" title="label">40</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Musiol</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">An overview of quinoline as a privileged scaffold in cancer drug discovery</span>. <span class="source" tagx="source" title="source">Expert Opin Drug Discov</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">12</span>:<span class="fpage" tagx="fpage" title="fpage">583</span>â€"<span class="lpage" tagx="lpage" title="lpage">97</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28399679">28399679</a></span></span></li> <li tag="ref"><a name="CIT0041" /><span class="label" tagx="label" title="label">41</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Solomon</span><span class="given-names" tagx="given-names" title="given-names">VR</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">H.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Quinoline as a privileged scaffold in cancer drug discovery</span>. <span class="source" tagx="source" title="source">Curr Med Chem</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">18</span>:<span class="fpage" tagx="fpage" title="fpage">1488</span>â€"<span class="lpage" tagx="lpage" title="lpage">508</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21428893">21428893</a></span></span></li> <li tag="ref"><a name="CIT0042" /><span class="label" tagx="label" title="label">42</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Shuai</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Discovery of novel quinoline-chalcone derivatives as potent antitumor agents with microtubule polymerization inhibitory activity</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">62</span>:<span class="fpage" tagx="fpage" title="fpage">993</span>â€"<span class="lpage" tagx="lpage" title="lpage">1013</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30525584">30525584</a></span></span></li> <li tag="ref"><a name="CIT0043" /><span class="label" tagx="label" title="label">43</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ma</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Shen</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel 4-acrylamido-quinoline derivatives as potent pi3k/mtor dual inhibitors: The design, synthesis, and inÂ vitro and inÂ vivo biological evaluation</span>. <span class="source" tagx="source" title="source">Front Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">7</span>:<span class="fpage" tagx="fpage" title="fpage">236</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31069214">31069214</a></span></span></li> <li tag="ref"><a name="CIT0044" /><span class="label" tagx="label" title="label">44</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wu</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">Q</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">W.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Recent advances in heterocyclic tubulin inhibitors targeting the colchicine binding site</span>. <span class="source" tagx="source" title="source">Anticancer Agents Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">16</span>:<span class="fpage" tagx="fpage" title="fpage">1325</span>â€"<span class="lpage" tagx="lpage" title="lpage">38</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26899186">26899186</a></span></span></li> <li tag="ref"><a name="CIT0045" /><span class="label" tagx="label" title="label">45</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Nainwal</span><span class="given-names" tagx="given-names" title="given-names">LM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Alam</span><span class="given-names" tagx="given-names" title="given-names">MM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Shaquiquzzaman</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Marella</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Combretastatin-based compounds with therapeutic characteristics: a patent review</span>. <span class="source" tagx="source" title="source">Expert Opin Ther Pat</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">29</span>:<span class="fpage" tagx="fpage" title="fpage">703</span>â€"<span class="lpage" tagx="lpage" title="lpage">31</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31369715">31369715</a></span></span></li> <li tag="ref"><a name="CIT0046" /><span class="label" tagx="label" title="label">46</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chaudhary</span><span class="given-names" tagx="given-names" title="given-names">V</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Venghateri</span><span class="given-names" tagx="given-names" title="given-names">JB</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Dhaked</span><span class="given-names" tagx="given-names" title="given-names">HPS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel combretastatin-2-aminoimidazole analogues as potent tubulin assembly inhibitors: exploration of unique pharmacophoric impact of bridging skeleton and aryl moiety</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">59</span>:<span class="fpage" tagx="fpage" title="fpage">3439</span>â€"<span class="lpage" tagx="lpage" title="lpage">51</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26938120">26938120</a></span></span></li> <li tag="ref"><a name="CIT0047" /><span class="label" tagx="label" title="label">47</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Jain</span><span class="given-names" tagx="given-names" title="given-names">KS</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kathiravan</span><span class="given-names" tagx="given-names" title="given-names">MK</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bariwal</span><span class="given-names" tagx="given-names" title="given-names">JB</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel dual use of formamide-pocl3 mixture for the efficient, one-pot synthesis of condensed 2â€‰h-pyrimidin-4-amine libraries under microwave irradiation</span>. <span class="source" tagx="source" title="source">Synth Commun</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">43</span>:<span class="fpage" tagx="fpage" title="fpage">719</span>â€"<span class="lpage" tagx="lpage" title="lpage">27</span>.</span></li> <li tag="ref"><a name="CIT0048" /><span class="label" tagx="label" title="label">48</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ibrahim</span><span class="given-names" tagx="given-names" title="given-names">TS</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bokhtia</span><span class="given-names" tagx="given-names" title="given-names">RM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">AL-Mahmoudy</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and biological evaluation of novel 5-((substituted quinolin-3-yl/1-naphthyl) methylene)-3-substituted imidazolidin-2,4-dione as HIV-1 fusion inhibitors</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">99</span>:<span class="fpage" tagx="fpage" title="fpage">103782</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32229348">32229348</a></span></span></li> <li tag="ref"><a name="CIT0049" /><span class="label" tagx="label" title="label">49</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kapoor</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Srivastava</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Panda</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in mcf-7 cells: implications in cancer chemotherapy</span>. <span class="source" tagx="source" title="source">Sci Rep</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">8</span>:<span class="fpage" tagx="fpage" title="fpage">12363</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30120268">30120268</a></span></span></li> <li tag="ref"><a name="CIT0050" /><span class="label" tagx="label" title="label">50</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lai</span><span class="given-names" tagx="given-names" title="given-names">MJ</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ojha</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lin</span><span class="given-names" tagx="given-names" title="given-names">MH</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">1-arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">162</span>:<span class="fpage" tagx="fpage" title="fpage">612</span>â€"<span class="lpage" tagx="lpage" title="lpage">30</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30476825">30476825</a></span></span></li> <li tag="ref"><a name="CIT0051" /><span class="label" tagx="label" title="label">51</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Du</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lin</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ji</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A novel orally active microtubule destabilizing agent s-40 targets the colchicine-binding site and shows potent antitumor activity</span>. <span class="source" tagx="source" title="source">Cancer Lett</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">495</span>:<span class="fpage" tagx="fpage" title="fpage">22</span>â€"<span class="lpage" tagx="lpage" title="lpage">32</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32931884">32931884</a></span></span></li> <li tag="ref"><a name="CIT0052" /><span class="label" tagx="label" title="label">52</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mohamed</span><span class="given-names" tagx="given-names" title="given-names">KO</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zaki</span><span class="given-names" tagx="given-names" title="given-names">I</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">El-Deen</span><span class="given-names" tagx="given-names" title="given-names">IM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Abdelhameid</span><span class="given-names" tagx="given-names" title="given-names">MK.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A new class of diamide scaffold: design, synthesis and biological evaluation as potent antimitotic agents, tubulin polymerization inhibition and apoptosis inducing activity studies</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">84</span>:<span class="fpage" tagx="fpage" title="fpage">399</span>â€"<span class="lpage" tagx="lpage" title="lpage">409</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30551066">30551066</a></span></span></li> <li tag="ref"><a name="CIT0053" /><span class="label" tagx="label" title="label">53</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wu</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Yotnda</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Production and detection of reactive oxygen species (ros) in cancers</span>. <span class="source" tagx="source" title="source">J Vis Exp</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">3357</span>.</span></li> <li tag="ref"><a name="CIT0054" /><span class="label" tagx="label" title="label">54</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Hura</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Sawant</span><span class="given-names" tagx="given-names" title="given-names">AV</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kumari</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Combretastatin-inspired heterocycles as antitubulin anticancer agents</span>. <span class="source" tagx="source" title="source">ACS Omega</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">3</span>:<span class="fpage" tagx="fpage" title="fpage">9754</span>â€"<span class="lpage" tagx="lpage" title="lpage">69</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31459105">31459105</a></span></span></li> <li tag="ref"><a name="CIT0055" /><span class="label" tagx="label" title="label">55</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ayati</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Esmaeili</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Moghimi</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of 4-amino-5-cinnamoylthiazoles as chalcone-like anticancer agents</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">145</span>:<span class="fpage" tagx="fpage" title="fpage">404</span>â€"<span class="lpage" tagx="lpage" title="lpage">12</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29335206">29335206</a></span></span></li> <li tag="ref"><a name="CIT0056" /><span class="label" tagx="label" title="label">56</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mahapatra</span><span class="given-names" tagx="given-names" title="given-names">DK</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bharti</span><span class="given-names" tagx="given-names" title="given-names">SK</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Asati</span><span class="given-names" tagx="given-names" title="given-names">V.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Anti-cancer chalcones: structural and molecular target perspectives</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">98</span>:<span class="fpage" tagx="fpage" title="fpage">69</span>â€"<span class="lpage" tagx="lpage" title="lpage">114</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26005917">26005917</a></span></span></li> <li tag="ref"><a name="CIT0057" /><span class="label" tagx="label" title="label">57</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhou</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Yan</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Cao</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agents</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">138</span>:<span class="fpage" tagx="fpage" title="fpage">1114</span>â€"<span class="lpage" tagx="lpage" title="lpage">25</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28763646">28763646</a></span></span></li> <li tag="ref"><a name="CIT0058" /><span class="label" tagx="label" title="label">58</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Agha</span><span class="given-names" tagx="given-names" title="given-names">KA</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Abo-Dya</span><span class="given-names" tagx="given-names" title="given-names">NE</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ibrahim</span><span class="given-names" tagx="given-names" title="given-names">TS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">N-acylbenzotriazole: Convenient approach for protecting group-free monoacylation of symmetric diamines</span>. <span class="source" tagx="source" title="source">Monatsh Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">151</span>:<span class="fpage" tagx="fpage" title="fpage">589</span>â€"<span class="lpage" tagx="lpage" title="lpage">98</span>.</span></li> <li tag="ref"><a name="CIT0059" /><span class="label" tagx="label" title="label">59</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Florian</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mitchison</span><span class="given-names" tagx="given-names" title="given-names">TJ.</span></span></span><span class="chapter-title" tagx="chapter-title" title="chapter-title">Anti-microtubule drugs</span>. In: <span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chang</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ohi</span><span class="given-names" tagx="given-names" title="given-names">R</span></span></span>, ed. <span class="source" tagx="source" title="source">The mitotic spindle</span>. <span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">New York (NY)</span>: <span class="publisher-name" tagx="publisher-name" title="publisher-name">Humana</span>; <span class="year" tagx="year" title="year">2016</span>:<span class="fpage" tagx="fpage" title="fpage">403</span>â€"<span class="lpage" tagx="lpage" title="lpage">421</span>.</span></li> <li tag="ref"><a name="CIT0060" /><span class="label" tagx="label" title="label">60</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ansari</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Shokrzadeh</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Karima</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">New thiazole-2 (3h)-thiones containing 4-(3, 4, 5-trimethoxyphenyl) moiety as anticancer agents</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">185</span>:<span class="fpage" tagx="fpage" title="fpage">111784</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31669850">31669850</a></span></span></li> <li tag="ref"><a name="CIT0061" /><span class="label" tagx="label" title="label">61</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Greene</span><span class="given-names" tagx="given-names" title="given-names">LM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Meegan</span><span class="given-names" tagx="given-names" title="given-names">MJ</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zisterer</span><span class="given-names" tagx="given-names" title="given-names">DM.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Combretastatins: More than just vascular targeting agents?</span><span class="source" tagx="source" title="source">J Pharmacol Exp Ther</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">355</span>:<span class="fpage" tagx="fpage" title="fpage">212</span>â€"<span class="lpage" tagx="lpage" title="lpage">27</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26354991">26354991</a></span></span></li> <li tag="ref"><a name="CIT0062" /><span class="label" tagx="label" title="label">62</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Agut</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Falomir</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Murga</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis of combretastatin a-4 and 3â€²-aminocombretastatin a-4 derivatives with aminoacid containing pendants and study of their interaction with tubulin and as downregulators of the vegf, htert and c-myc gene expression</span>. <span class="source" tagx="source" title="source">Molecules</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">25</span>:<span class="fpage" tagx="fpage" title="fpage">660</span>.</span></li> <li tag="ref"><a name="CIT0063" /><span class="label" tagx="label" title="label">63</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">PÃ©rez-PÃ©rez</span><span class="given-names" tagx="given-names" title="given-names">MJ</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Priego</span><span class="given-names" tagx="given-names" title="given-names">EM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bueno</span><span class="given-names" tagx="given-names" title="given-names">O</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Blocking blood flow to solid tumors by destabilizing tubulin: An approach to targeting tumor growth</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">59</span>:<span class="fpage" tagx="fpage" title="fpage">8685</span>â€"<span class="lpage" tagx="lpage" title="lpage">711</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27348355">27348355</a></span></span></li> <li tag="ref"><a name="CIT0064" /><span class="label" tagx="label" title="label">64</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Shobeiri</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Rashedi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mosaffa</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of quinoline analogues of flavones as potential anticancer agents and tubulin polymerization inhibitors</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">114</span>:<span class="fpage" tagx="fpage" title="fpage">14</span>â€"<span class="lpage" tagx="lpage" title="lpage">23</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26974371">26974371</a></span></span></li> <li tag="ref"><a name="CIT0065" /><span class="label" tagx="label" title="label">65</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mendez</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Policarpi</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Cenciarelli</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Role of bim in apoptosis induced in h460 lung tumor cells by the spindle poison combretastatin-a4</span>. <span class="source" tagx="source" title="source">Apoptosis</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">16</span>:<span class="fpage" tagx="fpage" title="fpage">940</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21671007">21671007</a></span></span></li> <li tag="ref"><a name="CIT0066" /><span class="label" tagx="label" title="label">66</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Tarade</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ma</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Pignanelli</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Structurally simplified biphenyl combretastatin a4 derivatives retain inÂ vitro anti-cancer activity dependent on mitotic arrest</span>. <span class="source" tagx="source" title="source">PLoS One</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">12</span>:<span class="fpage" tagx="fpage" title="fpage">e0171806</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28253265">28253265</a></span></span></li> <li tag="ref"><a name="CIT0067" /><span class="label" tagx="label" title="label">67</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Naaz</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ahmad</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lone</span><span class="given-names" tagx="given-names" title="given-names">BA</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design and synthesis of newer 1,3,4-oxadiazole and 1,2,4-triazole based topsentin analogues as anti-proliferative agent targeting tubulin</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">95</span>:<span class="fpage" tagx="fpage" title="fpage">103519</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31884140">31884140</a></span></span></li> <li tag="ref"><a name="CIT0068" /><span class="label" tagx="label" title="label">68</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Hua</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gou</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">189</span>:<span class="fpage" tagx="fpage" title="fpage">112041</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31954880">31954880</a></span></span></li> <li tag="ref"><a name="CIT0069" /><span class="label" tagx="label" title="label">69</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bortolozzi</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Carta</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Dal PrÃ </span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Evaluating the effects of fluorine on biological properties and metabolic stability of some antitubulin 3-substituted 7-phenyl-pyrroloquinolinones</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">178</span>:<span class="fpage" tagx="fpage" title="fpage">297</span>â€"<span class="lpage" tagx="lpage" title="lpage">314</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31195171">31195171</a></span></span></li> <li tag="ref"><a name="CIT0070" /><span class="label" tagx="label" title="label">70</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Xiong</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mu</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Jiang</span><span class="given-names" tagx="given-names" title="given-names">X.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Mitochondria-mediated apoptosis in mammals</span>. <span class="source" tagx="source" title="source">Protein &amp;amp; Cell</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">5</span>:<span class="fpage" tagx="fpage" title="fpage">737</span>â€"<span class="lpage" tagx="lpage" title="lpage">49</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25073422">25073422</a></span></span></li> <li tag="ref"><a name="CIT0071" /><span class="label" tagx="label" title="label">71</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">YR</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Jia</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">YJ</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">XZ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Novel dibenzoxanthenes compounds inhibit human gastric cancer sgc-7901 cell growth by apoptosis</span>. <span class="source" tagx="source" title="source">J Mol Struct</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">1220</span>:<span class="fpage" tagx="fpage" title="fpage">128588</span>.</span></li> <li tag="ref"><a name="CIT0072" /><span class="label" tagx="label" title="label">72</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Romagnoli</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Baraldi</span><span class="given-names" tagx="given-names" title="given-names">PG</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Prencipe</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design and synthesis of potent inÂ vitro and inÂ vivo anticancer agents based on 1-(3',4',5'-Trimethoxyphenyl)-2-Aryl-1H-Imidazole</span>. <span class="source" tagx="source" title="source">Sci Rep</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">6</span>:<span class="fpage" tagx="fpage" title="fpage">26602</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27216165">27216165</a></span></span></li> <li tag="ref"><a name="CIT0073" /><span class="label" tagx="label" title="label">73</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Romagnoli</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Baraldi</span><span class="given-names" tagx="given-names" title="given-names">PG</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Prencipe</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of 2-methyl-4,5-disubstituted oxazoles as a novel class of highly potent antitubulin agents</span>. <span class="source" tagx="source" title="source">Sci Rep</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">7</span>:<span class="fpage" tagx="fpage" title="fpage">46356</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28406191">28406191</a></span></span></li> </ul> </div> </div>  </body></html>